Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Chronic Heart Failure

  Free Subscription


Articles published in Eur J Heart Fail

Retrieve available abstracts of 898 articles:
HTML format



Single Articles


    August 2022
  1. ANTOHI LE, Adamo M, Chioncel O
    Long-term Survival after Acute Heart Failure Hospitalization; From Observation to Collaborative Interventions.
    Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2645.
    PubMed    


    July 2022
  2. BORIANI G, Vitolo M, Imberti JF
    Effectiveness of atrial fibrillation ablation in heart failure across the entire spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2022 Jul 29. doi: 10.1002/ejhf.2642.
    PubMed    


  3. CHATUR S, Vaduganathan M, Peikert A, Claggett BL, et al
    Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial.
    Eur J Heart Fail. 2022 Jul 27. doi: 10.1002/ejhf.2638.
    PubMed     Abstract available


  4. METRA M, Jankowska EA, Pagnesi M, Anker SD, et al
    Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
    Eur J Heart Fail. 2022 Jul 23. doi: 10.1002/ejhf.2630.
    PubMed    


  5. VADUGANATHAN M, Ferreira JP, Rossignol P, Neuen B, et al
    Effects of Steroidal Mineralocorticoid Receptor Antagonists on Acute and Chronic Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Heart Failure.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2635.
    PubMed     Abstract available


  6. SALAH HM, Fudim M
    Tolerability and Safety Barriers of SGLT2 Inhibitors Initiation in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2633.
    PubMed    


  7. BROMAGE DI, Cannata A, McDonagh TA
    Combination diuretic therapy for acute heart failure: "Alone we can do so little; together we can do so much".
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2634.
    PubMed    


  8. METRA M, Chioncel O, Cotter G, Davison B, et al
    Safety and Efficacy of Istaroxime for Patients with Acute-Heart-Failure-Related Pre-cardiogenic Shock - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study (SEISMiC).
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2629.
    PubMed     Abstract available


  9. CARAVITA S, Faini A, Vignati C, Pelucchi S, et al
    Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2628.
    PubMed     Abstract available


  10. LINDE C, Grabowski M, Ponikowski P, Rao I, et al
    Cardiac Contractility Modulation Therapy Improves Health Status in Patients with Heart Failure with Preserved Ejection Fraction; a Pilot Study (CCM-HFpEF).
    Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2619.
    PubMed     Abstract available


  11. TOMASONI D, Aimo A, Merlo M, Nardi M, et al
    Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.
    Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2616.
    PubMed     Abstract available


  12. PAPALIA F, Charles-Edwards G, Okonko DO
    Reply to the letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2625.
    PubMed    


  13. DANDEL M, Hetzer R
    Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2622.
    PubMed    


  14. GENTILE F, Passino C, Emdin M, Giannoni A, et al
    Baroreflex activation therapy in heart failure: targeting the right patient.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2627.
    PubMed    


  15. REDDY YNV, Sundaram V
    Spironolactone, fibrosis and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2626.
    PubMed    


  16. KRISTENSEN SL, Gustafsson F
    Advanced Heart Failure: time to screen?
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2624.
    PubMed    


  17. JANSE RJ, Fu EL, Dahlstrom U, Benson L, et al
    Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2620.
    PubMed     Abstract available


  18. CHUNAWALA ZS, Qamar A, Arora S, Pandey A, et al
    Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: The ARIC study community surveillance.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2617.
    PubMed     Abstract available


  19. KOZHUHAROV N, Martin J, Wussler D, Lopez-Ayala P, et al
    Clinical Effect of Obesity on NT-proBNP Cut-off Concentrations for the Diagnosis of Acute Heart Failure.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2618.
    PubMed     Abstract available


  20. POCOCK SJ, Ferreira JP, Packer M, Zannad F, et al
    Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2022 Jul 7. doi: 10.1002/ejhf.2607.
    PubMed     Abstract available


  21. MERKELY B, Geller L, Zima E, Osztheimer I, et al
    Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2609.
    PubMed     Abstract available


  22. SENNI M, Alemayehu WG, Sim D, Edelmann F, et al
    Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2608.
    PubMed     Abstract available


  23. WANG X, Cunningham JW
    Restoring Balance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2599.
    PubMed    


  24. KRISTENSEN SL, Barasa A, Thune JJ
    The Challenge of Addressing Heart Failure in Low and Middle Income Countries.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2598.
    PubMed    


  25. BAYES-GENIS A, Aimo A, Lupon J
    Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2597.
    PubMed    


  26. GULIZIA MM, Orso F, Mortara A, Lucci D, et al
    BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines.
    Eur J Heart Fail. 2022 Jul 3. doi: 10.1002/ejhf.2605.
    PubMed     Abstract available


  27. VON OLSHAUSEN G, Benson L, Dahlstrom U, Lund LH, et al
    Catheter Ablation for Patients with Atrial Fibrillation and Heart Failure: Insights from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Jul 2. doi: 10.1002/ejhf.2604.
    PubMed     Abstract available


  28. VRTOVEC B, Frljak S, Poglajen G, Zemljic G, et al
    A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION.
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2596.
    PubMed     Abstract available


  29. MARCO GUAZZI M, Wilhelm M, Halle M, Van Craenenbroeck E, et al
    Exercise Testing in HFpEF: an Appraisal Through Diagnosis, Pathophysiology and Therapy A Clinical Consensus Statement of the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2601.
    PubMed     Abstract available



  30. Abstracts of the Heart Failure 2022 and the World Congress on Acute Heart Failure, 21 - 24 May 2022, Madrid, Spain.
    Eur J Heart Fail. 2022;24 Suppl 2:3-282.
    PubMed    


  31. TOMASONI D, Adamo M, Metra M
    July 2022 at a glance: focus on prognosis, devices and valvular heart disease.
    Eur J Heart Fail. 2022;24:1145-1147.
    PubMed    


  32. SCHRAGE B, Westermann D
    Enough iron in transcatheter aortic valve implantation already.
    Eur J Heart Fail. 2022;24:1280-1281.
    PubMed    


  33. DOMINGUEZ F
    Predicting pacemaker implantation in cardiac amyloidosis: let's start with an ECG.
    Eur J Heart Fail. 2022;24:1237-1238.
    PubMed    


  34. MCGURK KA, Halliday BP
    Dilated cardiomyopathy - details make the difference.
    Eur J Heart Fail. 2022;24:1197-1199.
    PubMed    


  35. PETUTSCHNIGG J, Edelmann F
    Closing the gap, or the beauty of alleviating our patients' symptoms.
    Eur J Heart Fail. 2022;24:1302-1304.
    PubMed    


  36. BORIANI G, Vitolo M, Leyva F
    Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'?
    Eur J Heart Fail. 2022;24:1223-1226.
    PubMed    


  37. NAYAK A, Mehra MR
    Global challenges in left ventricular assist device therapy: a tale across two continents.
    Eur J Heart Fail. 2022;24:1316-1318.
    PubMed    


  38. ILIADIS C, Kalbacher D, Lurz P, Petrescu AM, et al
    Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation.
    Eur J Heart Fail. 2022;24:1282-1292.
    PubMed     Abstract available


  39. KVASLERUD AB, Bardan S, Andresen K, Klove SF, et al
    Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial.
    Eur J Heart Fail. 2022;24:1269-1279.
    PubMed     Abstract available


  40. PORCARI A, Rossi M, Cappelli F, Canepa M, et al
    Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1227-1236.
    PubMed     Abstract available


  41. JAKUS N, Brugts JJ, Claggett B, Timmermans P, et al
    Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry.
    Eur J Heart Fail. 2022;24:1305-1315.
    PubMed     Abstract available


  42. MIRELIS JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, et al
    Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1183-1196.
    PubMed     Abstract available


  43. MANCA P, Stolfo D, Merlo M, Gregorio C, et al
    Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1171-1179.
    PubMed     Abstract available


  44. STOCKER TJ, Cohen DJ, Arnold SV, Sommer S, et al
    Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy.
    Eur J Heart Fail. 2022;24:1293-1301.
    PubMed     Abstract available


    June 2022
  45. ABDELHAMID M, Rosano G, Metra M, Adamopoulos S, et al
    Prevention of sudden death in heart failure with reduced ejection fraction: Do we still need ICD for primary prevention?
    Eur J Heart Fail. 2022 Jun 26. doi: 10.1002/ejhf.2594.
    PubMed     Abstract available


  46. HARIHARAPUTHIRAN S, Peng Y, Ngo L, Ali A, et al
    Long-term Survival and Life Expectancy Following an Acute Heart Failure Hospitalisation in Australia and New Zealand.
    Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2595.
    PubMed     Abstract available


  47. INCIARDI RM, Pagnesi M, Lombardi CM, Anker SD, et al
    Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
    Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2593.
    PubMed     Abstract available


  48. MULLENS W, Dauw J, Martens P, Meekers E, et al
    Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline Characteristics.
    Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2587.
    PubMed     Abstract available


  49. VUKADINOVIC D, Abdin A, Anker SD, Rosano GM, et al
    Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2584.
    PubMed     Abstract available


  50. RYAN M, Perera D, Petrie MC
    Revascularization and heart failure with preserved ejection fraction - time for randomized trials.
    Eur J Heart Fail. 2022 Jun 21. doi: 10.1002/ejhf.2583.
    PubMed    


  51. REDDY YNV
    Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil.
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2582.
    PubMed    


  52. AIMO A, Castiglione V, Bayes-Genis A
    Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2580.
    PubMed    


  53. COATS A, Abraham WT, Zile MR, Lindenfeld JA, et al
    Baroreflex activation therapy with the barostim device in patients with heart failure with reduced ejection fraction: A patient level meta-analysis of randomized controlled trials.
    Eur J Heart Fail. 2022 Jun 17. doi: 10.1002/ejhf.2573.
    PubMed     Abstract available


  54. KOBAYASHI M, Girerd N, Ferreira JP, Kevin D, et al
    The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2579.
    PubMed     Abstract available


  55. BURRAGE MK, Valkovic L, Rider OJ
    Letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2574.
    PubMed    


  56. SEFEROVIC P, Farmakis D, Bayes-Genis A, Ben Gal T, et al
    Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2575.
    PubMed     Abstract available


  57. LUND LH, Pitt B, Metra M
    Left ventricular ejection fraction as the primary heart failure phenotyping parameter.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2576.
    PubMed    


  58. INCIARDI RM, Chandra A
    Epicardial Adipose Tissue in Heart Failure: Risk Factor or Mediator?
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2577.
    PubMed    


  59. BHATT AS, Vaduganathan M, Solomon SD, Schneeweiss S, et al
    Sacubitril/Valsartan Use Patterns among Older Adults with Heart Failure in Clinical Practice: A Population-Based Cohort Study of >25,000 Medicare Beneficiaries.
    Eur J Heart Fail. 2022 Jun 11. doi: 10.1002/ejhf.2572.
    PubMed     Abstract available


  60. RAGAVAN A, Hogan J, Halliday BP
    The spectrum of heart failure with improved ejection fraction - persistent congestion, to heart failure remission and perhaps recovery?
    Eur J Heart Fail. 2022 Jun 6. doi: 10.1002/ejhf.2571.
    PubMed    


  61. HAVAKUK O, Topilsky Y
    The Impact of Early Surgery on Mortality in Infective Endocarditis Complicated by Heart Failure - How Much More Data Do We Need?
    Eur J Heart Fail. 2022 Jun 1. doi: 10.1002/ejhf.2567.
    PubMed    


  62. TOMASONI D, Adamo M, Metra M
    June 2022 at a glance: prevention, outcomes and treatment.
    Eur J Heart Fail. 2022;24:913-915.
    PubMed    


  63. LEYVA F, Boriani G
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1091-1093.
    PubMed    


  64. COOPER LT JR
    Sex and autoimmunity in acute myocarditis: time for a refresh.
    Eur J Heart Fail. 2022;24:1045-1046.
    PubMed    


  65. CLELAND JGF, Bristow MR, Freemantle N, Olshansky B, et al
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1080-1090.
    PubMed     Abstract available


  66. YAMAMOTO M, Tajiri K, Ayuzawa S, Ieda M, et al
    Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination.
    Eur J Heart Fail. 2022;24:1132-1138.
    PubMed     Abstract available


  67. BARITUSSIO A, Schiavo A, Basso C, Giordani AS, et al
    Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies.
    Eur J Heart Fail. 2022;24:1033-1044.
    PubMed     Abstract available


  68. GONZALEZ A, Richards AM, de Boer RA, Thum T, et al
    Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022;24:927-943.
    PubMed     Abstract available


  69. MARTENS P, Dupont M, Dauw J, Nijst P, et al
    The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
    Eur J Heart Fail. 2022;24:1106-1113.
    PubMed     Abstract available


  70. CHIANG CH, Chiang CH, Chiang CH
    Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'.
    Eur J Heart Fail. 2022;24:1142-1143.
    PubMed    


  71. MCDOWELL K, Welsh P, Docherty KF, Morrow DA, et al
    Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
    Eur J Heart Fail. 2022;24:1066-1076.
    PubMed     Abstract available


    May 2022

  72. Corrigendum to 'A population-based study of 92 clinicallyrecognized risk factors for heart failure: co-occurrence, prognosis and preventive potential' [Eur J Heart Fail 2022;24:466-480].
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2544.
    PubMed    


  73. ANKER SD, Siddiqi TJ, Filippatos G, Zannad F, et al
    Outcomes with Empagliflozin in Heart Failure with Preserved Ejection Fraction Using DELIVER-like Endpoint Definitions.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2558.
    PubMed     Abstract available


  74. PALAU P, Amiguet M, Dominguez E, Sastre C, et al
    Short-term Effects of Dapagliflozin on Maximal Functional Capacity in Heart Failure with Reduced Ejection Fraction (DAPA-VO2 ): A Randomized Clinical Trial.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2560.
    PubMed     Abstract available


  75. PAGNESI M, Lombardi CM, Chiarito M, Stolfo D, et al
    Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: Results from the HELP-HF Registry.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2561.
    PubMed     Abstract available


  76. SORIMACHI H, Omote K, Omar M, Popovic D, et al
    Sex and Central Obesity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2563.
    PubMed     Abstract available


  77. INCIARDI RM, Bonelli A, Biering-Sorensen T, Cameli M, et al
    Left atrial disease and left atrial reverse remodeling across different stages of heart failure development and progression: a new target for prevention and treatment.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2562.
    PubMed     Abstract available


  78. FUDIM M, Fail PS, Litwin SE, Shaburishvili T, et al
    Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Early Results of the REBALANCE-HF Trial Roll-in Cohort.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2559.
    PubMed     Abstract available


  79. COOPER TJ, Cleland JG, Guazzi M, Pellicori P, et al
    Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial.
    Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2527.
    PubMed     Abstract available


  80. RAVERA A, Santema BT, de Boer RA, Anker SD, et al
    Distinct pathophysiological pathways in women and men with heart failure.
    Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2534.
    PubMed     Abstract available


  81. JANUS SE, Hajjari J, Chami T, Mously H, et al
    Multi-Variable Biomarker Approach in Identifying Incident Heart Failure in Chronic Kidney Disease Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Eur J Heart Fail. 2022 May 19. doi: 10.1002/ejhf.2543.
    PubMed     Abstract available


  82. BAYES-GENIS A, Aimo A, Metra M, Anker S, et al
    Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines.
    Eur J Heart Fail. 2022 May 17. doi: 10.1002/ejhf.2542.
    PubMed     Abstract available


  83. JOHANSSON I, Balasubramanian K, Bangdiwala S, Mielniczuk L, et al
    Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: Results of the G-CHF Research Program.
    Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2535.
    PubMed     Abstract available


  84. NATH M, Romaine SP, Koekemoer A, Hamby S, et al
    Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.
    Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2540.
    PubMed     Abstract available


  85. VAN ESSEN B, Voors AA, Tromp J
    Risk factors for the development of heart failure in patients with or without prior myocardial infarction.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2538.
    PubMed    


  86. ASLEH R, Briasoulis A, Borlaug BA
    Nonsteroidal Aldosterone Receptor Antagonism: A "Fine" Treatment for Heart Failure Patients?
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2537.
    PubMed    


  87. DAMMAN K
    When two worlds collide - Making sense of changes in renal function with life saving heart failure therapies.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2539.
    PubMed    


  88. MYHRE PL, Claggett BL, Shah AM, Prescott MF, et al
    Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2541.
    PubMed     Abstract available


  89. BOHBOT Y, Habib G, Laroche C, Stohr E, et al
    Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: A substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry.
    Eur J Heart Fail. 2022 May 4. doi: 10.1002/ejhf.2525.
    PubMed     Abstract available


  90. SCHRAGE B, Lund LH, Benson L, Dahlstrom U, et al
    Predictors of primary prevention implantable cardioverter defibrillator use in heart failure with reduced ejection fraction: Impact of the predicted risk of sudden cardiac death and all-cause mortality.
    Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2530.
    PubMed     Abstract available


  91. ERQOU S, Adler AI, Challa AA, Fonarow GC, et al
    Insulin Resistance and Incident Heart Failure: A Meta-Analysis.
    Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2531.
    PubMed    


  92. TOMASONI D, Adamo M, Metra M
    May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices.
    Eur J Heart Fail. 2022;24:735-737.
    PubMed    


  93. COATS AJS
    What's all the fuss about a new guideline?
    Eur J Heart Fail. 2022;24:743-745.
    PubMed    


  94. SORAJJA P, Cavalcante J, Bapat V
    Setting expectations for transcatheter mitral valve replacement in the real world.
    Eur J Heart Fail. 2022;24:908-909.
    PubMed    


  95. FRERKER C, Karam N, Hahn RT, Thiele H, et al
    New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence.
    Eur J Heart Fail. 2022;24:746-749.
    PubMed    


  96. REDDY YNV
    Using the ejection fraction to guide medical therapy: a necessary but imperfect first step.
    Eur J Heart Fail. 2022;24:779-781.
    PubMed    


  97. BEN ALI W, Ludwig S, Duncan A, Weimann J, et al
    Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry.
    Eur J Heart Fail. 2022;24:887-898.
    PubMed     Abstract available


  98. ROSANO GMC, Celant S, Olimpieri PP, Colatrella A, et al
    Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
    Eur J Heart Fail. 2022;24:855-860.
    PubMed     Abstract available


  99. BUTLER J, Spertus JA, Bamber L, Khan MS, et al
    Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
    Eur J Heart Fail. 2022;24:843-850.
    PubMed     Abstract available


  100. WILD MG, Kreidel F, Hell MM, Praz F, et al
    Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.
    Eur J Heart Fail. 2022;24:899-907.
    PubMed     Abstract available


    April 2022
  101. AIMO A, Vergaro G, Gonzalez A, Barison A, et al
    Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2022 Apr 30. doi: 10.1002/ejhf.2522.
    PubMed     Abstract available


  102. CARTER S, Hendren NS, Grodin JL
    Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
    Eur J Heart Fail. 2022 Apr 29. doi: 10.1002/ejhf.2516.
    PubMed    


  103. REZA N, Butler J
    Assessing Health Status After Discharge for Decompensated Heart Failure: A Patient-Centered Priority.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2521.
    PubMed    


  104. BORIANI G, Imberti JF, Vitolo M
    Dronedarone in the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long Odyssey?
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2519.
    PubMed    


  105. PELLICORI P, Cleland JG
    Heart failure: age is no excuse for complacency.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2517.
    PubMed    


  106. CANNATA A, Bromage DI, McDonagh TA
    COVID and heart failure: the dark side of the moon.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2518.
    PubMed    


  107. KALOGEROPOULOS AP, Tam E
    Intravenous iron in heart failure with reduced ejection fraction: just about right.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2520.
    PubMed    


  108. JIN X, Hung CL, Tay WT, Soon D, et al
    Epicardial Adipose Tissue related to Left Atrial and Ventricular Function in Heart Failure with Preserved (HFpEF) versus Reduced and Mildly Reduced Ejection Fraction (HFrEF/HFmrEF).
    Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2513.
    PubMed     Abstract available


  109. XIE C
    Could angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor be used in heart failure patients with atrial fibrillation and low blood pressure?
    Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2515.
    PubMed    


  110. EMDIN M, Aimo A, Castiglione V
    Is Targeting Cyclic Guanosine Monophosphate by Vericiguat Effective to Treat Ischaemic Heart Failure with Reduced Ejection Fraction? Yes, It Is.
    Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2511.
    PubMed    


  111. STRAW S, Gierula J, Witte KK
    Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?
    Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2510.
    PubMed    


  112. MCNAUGHTON CD, McConnachie A, Cleland JG, Spertus JA, et al
    Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from REPORT-HF (International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).
    Eur J Heart Fail. 2022 Apr 16. doi: 10.1002/ejhf.2508.
    PubMed     Abstract available


  113. GIRERD N, Mewton N, Tartiere JM, Guijarro D, et al
    Practical outpatient management of worsening chronic heart failure.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2503.
    PubMed     Abstract available


  114. STEWART COATS AJ
    HeartFailureNews Figures of the Heart Failure Association: Professor Finn Gustafsson, Board Member, 2020-2022.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2502.
    PubMed    


  115. KALOGEROPOULOS AP, Butler J
    Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2507.
    PubMed    


  116. STEWART COATS AJ
    Figures of the Heart Failure Association: Doctor Amina Rakisheva, Board Member, 2020-2022.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2499.
    PubMed    


  117. ALNUWAYSIR RIS, Grote Beverborg N, van der Meer P
    Fluctuating iron levels in heart failure: when and where to look at?
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2500.
    PubMed    


  118. VOORDES GHD, Heerspink HJL, Ter Maaten JM
    The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2501.
    PubMed    


  119. SINHA A, Yancy CW, Patel RB
    Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2505.
    PubMed    


  120. RASTOGI T, Ho FK, Rossignol P, Merkling T, et al
    Comparing and contrasting risk factors for Heart failure in patients with and without history of myocardial infarction: Data from HOMAGE and the UK Biobank.
    Eur J Heart Fail. 2022 Apr 1. doi: 10.1002/ejhf.2495.
    PubMed     Abstract available


  121. TOMASONI D, Adamo M, Metra M
    April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022;24:593-595.
    PubMed    


  122. CLELAND JGF, Butler J, Januzzi JL Jr, Pellicori P, et al
    Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice.
    Eur J Heart Fail. 2022;24:678-680.
    PubMed    


  123. GROTE BEVERBORG N
    The heart during iron deficiency: a non-rechargeable battery?
    Eur J Heart Fail. 2022;24:724-726.
    PubMed    


  124. TAVAZZI L, Maggioni AP, Rapezzi C, Ferrari R, et al
    Clinical trials: conventional or pragmatic?
    Eur J Heart Fail. 2022;24:596-599.
    PubMed    


  125. SIDHU K, Castrini AI, Parikh V, Reza N, et al
    The response to cardiac resynchronization therapy in LMNA cardiomyopathy.
    Eur J Heart Fail. 2022;24:685-693.
    PubMed     Abstract available


  126. CHIONCEL O, Adamo M, Bauersachs J
    Risk stratification in cardiogenic shock: from clinical utility to improving outcomes.
    Eur J Heart Fail. 2022;24:668-671.
    PubMed    


  127. MARINO PN, Zanaboni J
    Does left atrial deformation impact on symptoms and prognosis in functional mitral regurgitation patients with poor left ventricular function?
    Eur J Heart Fail. 2022;24:705-707.
    PubMed    


  128. HOLM H, Magnusson M, Jujic A, Bozec E, et al
    How to calculate ventricular-arterial coupling?
    Eur J Heart Fail. 2022;24:600-602.
    PubMed    


  129. HAVAKUK O, Topilsky Y
    The interplay between functional mitral regurgitation and left atrial function.
    Eur J Heart Fail. 2022;24:703-704.
    PubMed    


  130. IKONOMIDIS I, Lambadiari V, Mitrakou A, Kountouri A, et al
    Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection.
    Eur J Heart Fail. 2022;24:727-729.
    PubMed    


  131. BEER BN, Jentzer JC, Weimann J, Dabboura S, et al
    Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause - the Cardiogenic Shock Score.
    Eur J Heart Fail. 2022;24:657-667.
    PubMed     Abstract available


    March 2022
  132. NIJHOLT KT, Westenbrink BD
    Reply to letter to the editor regarding the article 'Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?'
    Eur J Heart Fail. 2022 Mar 26. doi: 10.1002/ejhf.2494.
    PubMed    


  133. ANKER SD, Ponikowski P, Khan MS, Friede T, et al
    Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Eur J Heart Fail. 2022 Mar 25. doi: 10.1002/ejhf.2491.
    PubMed     Abstract available



  134. Corrigendum to 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy' [Eur J Heart Fail 2021;23:854-871].
    Eur J Heart Fail. 2022 Mar 17. doi: 10.1002/ejhf.2474.
    PubMed    


  135. DEVORE AD, Hellkamp AS, Thomas L, Albert NM, et al
    The Association of Improvement in Left Ventricular Ejection Fraction with Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Data from CHAMP-HF.
    Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2486.
    PubMed     Abstract available


  136. VADUGANATHAN M, Piccini JP, Camm AJ, Crijns HJGM, et al
    Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial.
    Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2487.
    PubMed     Abstract available


  137. KESHVANI N, Mehta A, Alger HM, Rutan C, et al
    Heart Failure Quality of Care and In-Hospital Outcomes During the COVID-19 Pandemic Findings from the Get With The Guidelines-Heart Failure Registry.
    Eur J Heart Fail. 2022 Mar 14. doi: 10.1002/ejhf.2484.
    PubMed     Abstract available


  138. BUTLER J, Khan MS, Friede T, Jankowska EA, et al
    Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency.
    Eur J Heart Fail. 2022 Mar 13. doi: 10.1002/ejhf.2478.
    PubMed     Abstract available


  139. FORREST IS, Rocheleau G, Bafna S, Argulian E, et al
    Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure.
    Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2482.
    PubMed     Abstract available


  140. STOLFO D, Lund LH, Becher PM, Orsini N, et al
    Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.
    Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2483.
    PubMed     Abstract available



  141. Corrigendum to 'Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study
    Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2473.
    PubMed    



  142. Corrigendum to 'Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry [Eur J Heart Fail 2021;23:1844-1854].
    Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2472.
    PubMed    


  143. D'AMARIO D, Rodolico D, Rosano GM, Dahlstrom U, et al
    Association Between Dosing And Combination Use Of Medications And Outcomes In Heart Failure With Reduced Ejection Fraction: Data From The Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Mar 8. doi: 10.1002/ejhf.2477.
    PubMed     Abstract available


  144. KONSTAM MA
    Autonomic Dysregulation in Diabetes: CAN We Prevent Heart Failure?
    Eur J Heart Fail. 2022 Mar 4. doi: 10.1002/ejhf.2476.
    PubMed    


  145. SALDARRIAGA C, Atar D, Stebbins A, Lewis BS, et al
    Vericiguat in Patients with Coronary Artery Disease and Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2468.
    PubMed     Abstract available


  146. KHAN MS, Shahid I, Fonarow GC, Greene SJ, et al
    Classifying Heart Failure Based on Ejection Fraction: Imperfect but Enduring.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2470.
    PubMed    


  147. FILIPPATOS G, Pitt B, Agarwal R, Farmakis D, et al
    Finerenone in patients with CKD and T2D with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2469.
    PubMed     Abstract available


  148. MULLENS W, Martens P, Testani JM, Tang WHW, et al
    Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2471.
    PubMed    


  149. KOKHAN E, Kiyakbaev G, Medovchshikov V
    Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article "Early benefit with empagliflozin in heart failure with preserved ejecti
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2466.
    PubMed    


  150. ANDRIOPOULOU M, Dimaki N, Kallistratos MS, Chamodraka E, et al
    Skeletal muscle alterations and exercise intolerance in heart failure with preserved ejection fraction patients: ultrasonography assessment of diaphragm and quadriceps.
    Eur J Heart Fail. 2022 Mar 1. doi: 10.1002/ejhf.2462.
    PubMed    


  151. TOMASONI D, Adamo M, Metra M
    March 2022 at a glance: focus on medical therapy, prevention and comorbidities.
    Eur J Heart Fail. 2022;24:403-405.
    PubMed    


  152. DAUW J, Mullens W, Girerd N
    The fastest way to the heart is through the veins: towards a better understanding of congestion.
    Eur J Heart Fail. 2022;24:463-465.
    PubMed    


  153. KOEHLER F, Schulz M
    The AMULET menage a trois: nurse, telemedicine support, and remote cardiologist.
    Eur J Heart Fail. 2022;24:578-580.
    PubMed    


  154. DE SOUSA C, Pinto FJ
    Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence.
    Eur J Heart Fail. 2022;24:589-590.
    PubMed    


  155. DONAL E, Sade LE, Thomas L
    Left atrial function: the HbA1c for the cardiologist and even more.
    Eur J Heart Fail. 2022;24:494-496.
    PubMed    


  156. CURTAIN JP, Jackson AM, Shen L, Jhund PS, et al
    Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
    Eur J Heart Fail. 2022;24:551-561.
    PubMed     Abstract available


  157. RUSSO G, Taramasso M, Pedicino D, Gennari M, et al
    Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?
    Eur J Heart Fail. 2022;24:442-454.
    PubMed     Abstract available


  158. IVEY-MIRANDA JB, Wetterling F, Gaul R, Sheridan S, et al
    Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone.
    Eur J Heart Fail. 2022;24:455-462.
    PubMed     Abstract available


  159. AMAT-SANTOS IJ, Sanchez-Luna JP, Abu-Assi E, Melendo-Viu M, et al
    Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
    Eur J Heart Fail. 2022;24:581-588.
    PubMed     Abstract available


    February 2022
  160. BHATT AS, Fonarow GC, Greene SJ
    Prioritizing Prevention of De Novo and Worsening Chronic Heart Failure.
    Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2464.
    PubMed    


  161. KAMBIC T, Piepoli MF, Lainscak M
    Exercise intolerance in heart failure: beyond mitochondrial dysfunction.
    Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2461.
    PubMed    


  162. FERREIRA JP, Verdonschot JAJ, Girerd N, Bozec E, et al
    Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2455.
    PubMed     Abstract available


  163. BUTT JH, Adamson C, Docherty KF, Vaduganathan M, et al
    Eligibility for Pharmacological Therapies in Heart Failure with Reduced Ejection Fraction: Implications of the New CKD-EPI Creatinine Equation for Estimating Glomerular Filtration Rate.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2460.
    PubMed     Abstract available


  164. PAPALIA F, Jouhra F, Amin-Youssef G, Shah AM, et al
    Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2454.
    PubMed     Abstract available


  165. FERREIRA JP, Packer M, Butler J, Zannad F, et al
    Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.
    Eur J Heart Fail. 2022 Feb 22. doi: 10.1002/ejhf.2457.
    PubMed     Abstract available


  166. ROSSIGNOL P, Pitt B
    Time to Shift our Focus from the Treatment to the Prevention of Heart Failure with a Mineralocorticoid Receptor Antagonist (MRA)?
    Eur J Heart Fail. 2022 Feb 21. doi: 10.1002/ejhf.2459.
    PubMed    


  167. IKONOMIDIS I, Vlastos D
    Corrigendum to 'The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Periph
    Eur J Heart Fail. 2022 Feb 9. doi: 10.1002/ejhf.2452.
    PubMed    


  168. PEIKERT A, Vaduganathan M, McCausland F, Claggett BL, et al
    Effects of Sacubitril/Valsartan Versus Valsartan on Renal Function in Patients with and without Diabetes and Heart Failure with Preserved Ejection Fraction: Insights From PARAGON-HF.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2450.
    PubMed     Abstract available


  169. DEO SV, Reddy YN, Zakeri R, Karnib M, et al
    Revascularization in Ischemic Heart Failure with Preserved Ejection Fraction: A Nationwide Cohort Study.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2446.
    PubMed    


  170. MOHAMED MO
    Prevention is better than cure: modifiable risk factors for heart failure better understood.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2448.
    PubMed    


  171. KONDO T, Jhund PS, McMurray JJV
    Drug therapy for heart failure with reduced ejection fraction: what is the 'right' dose?
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2447.
    PubMed     Abstract available


  172. VARSHNEY AS, Singh JP, Vaduganathan M
    A Heart Team Approach to Contemporary Device Decision-Making in Heart Failure.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2445.
    PubMed    


  173. PITT B, Epstein M
    A Promise Unfulfilled : The use of Mineralocorticoid Receptor Antagonists ( MRAs ) in patients with Heart Failure and a Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2441.
    PubMed    


  174. ARITA VA, Van Veldhuisen DJ, Rienstra M
    Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2443.
    PubMed    


  175. EL-BATTRAWY I, Akin I
    Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baselin
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2444.
    PubMed    


  176. OMAR M, Jensen MD, Borlaug BA
    Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2440.
    PubMed    



  177. HFA Winter Meeting on Translational Heart Failure Research 27-28 January 2022.
    Eur J Heart Fail. 2022;24 Suppl 1:3-12.
    PubMed    


  178. TOMASONI D, Adamo M, Metra M
    February 2022 at a glance: focus on pathophysiology and acute heart failure.
    Eur J Heart Fail. 2022;24:243-244.
    PubMed    


  179. TREVISAN M, Fu EL, Carrero JJ
    Reply to the letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399-400.
    PubMed    


  180. WARRAICH HJ, Nohria A
    Is worsening renal function relevant without clinical context?
    Eur J Heart Fail. 2022;24:375-377.
    PubMed    


  181. FACILE A, Mewton N, Nguon M, Durand de Gevigney G, et al
    Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA(R) coding in the MITRA-FR study.
    Eur J Heart Fail. 2022;24:396-398.
    PubMed    


  182. ALEXANDROU ME, Sarafidis PA
    Letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399.
    PubMed    


  183. OBOKATA M, Reddy YNV, Melenovsky V, Sorimachi H, et al
    Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
    Eur J Heart Fail. 2022;24:353-361.
    PubMed     Abstract available


    January 2022
  184. PABON MA, Cunningham JW, Claggett BL, Packer M, et al
    Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF.
    Eur J Heart Fail. 2022 Jan 26. doi: 10.1002/ejhf.2439.
    PubMed     Abstract available


  185. KAZE AD, Yuyun MF, Erqou S, Fonarow GC, et al
    Cardiac Autonomic Neuropathy and Risk of Incident Heart Failure Among Adults with Type 2 Diabetes.
    Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2432.
    PubMed     Abstract available


  186. TROMP J, Beusekamp JC, Ouwerkerk W, van der Meer P, et al
    Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.
    Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2431.
    PubMed     Abstract available


  187. CHANDRAMOULI C, Ting TW, Tromp J, Agarwal A, et al
    Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2022 Jan 21. doi: 10.1002/ejhf.2435.
    PubMed     Abstract available


  188. MULLENS W, Coats A, Seferovic P, Metra M, et al
    Education and Certification on Heart Failure of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2430.
    PubMed     Abstract available


  189. POTTER E, Stephenson G, Harris J, Wright L, et al
    Screening-Guided Spironolactone Treatment of Subclinical Left Ventricular Dysfunction for Heart Failure Prevention in At-risk Patients.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2428.
    PubMed     Abstract available


  190. MALAGOLI A, Rossi L, Zanni A, Sticozzi C, et al
    Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2429.
    PubMed     Abstract available


  191. MC CAUSLAND FR, Lefkowitz MP, Claggett B, Packer M, et al
    Angiotensin-Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2421.
    PubMed     Abstract available


  192. PATEL RB, Shah SJ, Inciardi RM
    Collagen Homeostasis of the Left Atrium: An Emerging Treatment Target to Prevent Heart Failure?
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2422.
    PubMed    


  193. MADIAS JE
    Pathophysiology and therapy of Takotsubo syndrome. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Gro
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2413.
    PubMed    


  194. DOUMAS M, Patoulias D, Papadopoulos C
    Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, m
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2412.
    PubMed    


  195. CEELEN D, Voors AA, Tromp J, van Veldhuisen DJ, et al
    Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2424.
    PubMed     Abstract available


  196. BUTLER J, Siddiqi TJ, Filippatos G, Ferreira JP, et al
    Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2420.
    PubMed     Abstract available


  197. DE BIASE N, Del Punta L, Pugliese NR
    Reply: Epicardial adipose tissue: does it mediate the cardio-protective effects of SGLT-2 inhibitors in subjects with heart failure?
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2423.
    PubMed    


  198. PIEPOLI MF, Adamo M, Barison A, Bestetti RB, et al
    Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.
    Eur J Heart Fail. 2022;24:143-168.
    PubMed     Abstract available


  199. TOMASONI D, Adamo M, Metra M
    January 2022 at a glance: time for the new ESC guidelines on heart failure.
    Eur J Heart Fail. 2022;24:1-3.
    PubMed    


  200. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contri
    Eur J Heart Fail. 2022;24:4-131.
    PubMed     Abstract available


  201. AKTAA S, Polovina M, Rosano G, Abdin A, et al
    European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society o
    Eur J Heart Fail. 2022;24:132-142.
    PubMed     Abstract available


  202. ROSENKRANZ S, Channick R, Chin KM, Jenner B, et al
    The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    Eur J Heart Fail. 2022;24:205-214.
    PubMed     Abstract available


    December 2021
  203. ZAHIR D, Bonde A, Madelaire C, Malmborg M, et al
    Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017.
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2418.
    PubMed     Abstract available


  204. BANERJEE A, Pasea L, Chung SC, Direk K, et al
    A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential.
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2417.
    PubMed     Abstract available


  205. DE BOER RA, Heymans S, Backs J, Carrier L, et al
    Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society o
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2414.
    PubMed     Abstract available


  206. MEEMS LMG, van Veldhuisen DJ, de Boer RA
    Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out...?!
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2415.
    PubMed    


  207. KAPLON-CIESLICKA A, Benson L, Chioncel O, Crespo-Leiro MG, et al
    A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2021 Dec 27. doi: 10.1002/ejhf.2408.
    PubMed     Abstract available


  208. BAYES-GENIS A, Nunez J, Lupon J
    Dysglycemia and High Natriuretic Peptides: The Prelude to Heart Failure.
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2410.
    PubMed    


  209. NIJHOLT KT, Sanchez-Aguilera PI, Voorrips SN, de Boer RA, et al
    Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2407.
    PubMed     Abstract available


  210. FERREIRA JP, Anker SD, Butler J, Filippatos G, et al
    Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2409.
    PubMed     Abstract available


  211. AL-MUBARAK AA, Beverborg NG, Suthahar N, Gansevoort RT, et al
    High selenium levels associate with reduced risk of mortality and new onset heart failure: data from PREVEND.
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2405.
    PubMed     Abstract available



  212. Corrigendum to 'Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials' [Eur J Heart Fail 2020;11:2160-2171].
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2404.
    PubMed    


  213. ANDERSEN DM, Sengelov M, Olsen FJ, Marott JL, et al
    Measures of Left Atrial Function Predicts Incident Heart Failure in a Low Risk General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2406.
    PubMed     Abstract available


  214. JACKSON AM, Rorth R, Liu J, Kristensen SL, et al
    Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Dec 17. doi: 10.1002/ejhf.2403.
    PubMed     Abstract available


  215. WEIR RA, Clements S, Steedman T, Dargie HJ, et al
    Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow-up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial.
    Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2402.
    PubMed     Abstract available


  216. OMEROVIC E, Citro R, Bossone E, Redfors B, et al
    Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: Overview and the central role
    Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2400.
    PubMed     Abstract available


  217. TOMASONI D, Fonarow GC, Adamo M, Anker SD, et al
    Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2397.
    PubMed     Abstract available


  218. PAGNESI M, Butler J, Metra M
    Ejection fraction in heart failure: just become Emperor's new clothes?
    Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2399.
    PubMed    


  219. TOMASONI D, Adamo M, Metra M
    December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models.
    Eur J Heart Fail. 2021;23:1993-1994.
    PubMed    


  220. VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
    Prime time for machine learning to predict clinical outcomes in valvular heart disease?
    Eur J Heart Fail. 2021;23:2033-2034.
    PubMed    


  221. SINAGRA G, Porcari A, Fabris E, Merlo M, et al
    Standardizing the role of endomyocardial biopsy in current clinical practice worldwide.
    Eur J Heart Fail. 2021;23:1995-1998.
    PubMed    


  222. VIDULA MK, Orlenko A, Zhao L, Salvador L, et al
    Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.
    Eur J Heart Fail. 2021;23:2021-2032.
    PubMed     Abstract available


  223. STRACHINARU M, Nijveldt R, Vernooy K
    Arrhythmic risk management after acute myocarditis: never too early, only too late.
    Eur J Heart Fail. 2021;23:2055-2057.
    PubMed    


  224. HALLIDAY BP, de Marvao A, Thilaganathan B
    Peripartum cardiomyopathy and pre-eclampsia: two tips of the same iceberg.
    Eur J Heart Fail. 2021;23:2070-2072.
    PubMed    


  225. GENTILE P, Merlo M, Peretto G, Ammirati E, et al
    Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias.
    Eur J Heart Fail. 2021;23:2045-2054.
    PubMed     Abstract available


  226. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
    Eur J Heart Fail. 2021;23:2085-2090.
    PubMed     Abstract available


  227. JACKSON AM, Petrie MC, Frogoudaki A, Laroche C, et al
    Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.
    Eur J Heart Fail. 2021;23:2058-2069.
    PubMed     Abstract available


    November 2021
  228. RAVASSA S, Lopez B, Ferreira JP, Girerd N, et al
    Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling.
    Eur J Heart Fail. 2021 Nov 28. doi: 10.1002/ejhf.2394.
    PubMed     Abstract available



  229. Corrigendum to 'High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality' [Eur J Heart Fail 2021;23:919-932].
    Eur J Heart Fail. 2021 Nov 24. doi: 10.1002/ejhf.2383.
    PubMed    


  230. FAUCHIER L, Bisson A, Lip GYH
    Age, sex and clinical outcomes with digoxin vs beta-blocker in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2389.
    PubMed    


  231. ALNUWAYSIR RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, et al
    Additional Burden of Iron Deficiency in Heart Failure Patients beyond the Cardio-Renal-Anaemia Syndrome: Findings from the BIOSTAT-CHF Study.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2393.
    PubMed     Abstract available


  232. CULIC V
    Digoxin and beta-blockers in patients with heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2392.
    PubMed    


  233. NAITO R, Kasai T
    Bereavement of a child as a risk of heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2388.
    PubMed    


  234. MADIAS JE
    Pathophysiology of Takotsubo syndrome: still a puzzle. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2390.
    PubMed    


  235. MAEDER MT
    Selexipag and the Pulmonary Hypertension Continuum.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2387.
    PubMed    


  236. BUTLER J, Anker SD, Siddiqi TJ, Coats AJS, et al
    Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Eur J Heart Fail. 2021 Nov 20. doi: 10.1002/ejhf.2386.
    PubMed     Abstract available


  237. TER MAATEN JM, Beldhuis IE, van der Meer P, Krikken JA, et al
    Natriuresis guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.
    Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2385.
    PubMed     Abstract available


  238. EMMENS JE, Ter Maaten JM, Matsue Y, Figarska SM, et al
    Worsening renal function in acute heart failure in the context of diuretic response.
    Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2384.
    PubMed     Abstract available


  239. GREENE SJ, Butler J, Fonarow GC
    In-hospital Initiation of Quadruple Medical Therapy for Heart Failure: Making the Post-Discharge Vulnerable Phase Far Less Vulnerable.
    Eur J Heart Fail. 2021 Nov 14. doi: 10.1002/ejhf.2382.
    PubMed    


  240. BUTT JH, Docherty KF, Jhund PS, De Boer RA, et al
    Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF.
    Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.
    PubMed     Abstract available


  241. SEFEROVIC PM, Polovina M, Adlbrecht C, BElohlavek J, et al
    Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2378.
    PubMed     Abstract available


  242. FERREIRA JP, Liu J, Claggett BL, Vardeny O, et al
    Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT.
    Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2376.
    PubMed     Abstract available


  243. SEGAR MW, Khan MS, Patel KV, Vaduganathan M, et al
    Incorporation of Natriuretic Peptides with Clinical Risk-scores to Predict Heart Failure Among Individuals with Dysglycemia.
    Eur J Heart Fail. 2021 Nov 3. doi: 10.1002/ejhf.2375.
    PubMed     Abstract available


  244. COHEN-SOLAL A, Beauvais F
    New treatments for heart failure and exercise capacity.
    Eur J Heart Fail. 2021 Nov 1. doi: 10.1002/ejhf.2374.
    PubMed    


  245. GHANTOUS E, Topilsky Y
    Recovery of cardiac function following COVID-19.
    Eur J Heart Fail. 2021;23:1913-1915.
    PubMed    


  246. LASSEN MCH, Skaarup KG, Lind JN, Alhakak AS, et al
    Recovery of cardiac function following COVID-19 - ECHOVID-19: a prospective longitudinal cohort study.
    Eur J Heart Fail. 2021;23:1903-1912.
    PubMed     Abstract available


  247. LAMBADIARI V, Mitrakou A, Kountouri A, Thymis J, et al
    Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection.
    Eur J Heart Fail. 2021;23:1916-1926.
    PubMed     Abstract available


  248. DERDA AA, Garg A, Bar C, Thum T, et al
    Reply to 'COVID-19 severity, miR-21 targets, and common human genetic variation'.
    Eur J Heart Fail. 2021;23:1987-1988.
    PubMed    


  249. DINGSDAG SA, Clay OK, Quintero GA
    COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article 'Circulating cardiovascular microRNAs in critically ill COVID-19 patients'.
    Eur J Heart Fail. 2021;23:1986-1987.
    PubMed    


  250. TOMASONI D, Adamo M, Metra M
    November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices.
    Eur J Heart Fail. 2021;23:1803-1805.
    PubMed    


  251. WITTE KK, Goldberg SL, Kaye D, Starling R, et al
    Reply to 'Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation'.
    Eur J Heart Fail. 2021;23:1985-1986.
    PubMed    


  252. SEFEROVIC PM
    Reply to "Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy".
    Eur J Heart Fail. 2021;23:1984.
    PubMed    


  253. COTTER G, Davison B, Metra M, Sliwa K, et al
    Amended STRONG-HF study design.
    Eur J Heart Fail. 2021;23:1981-1982.
    PubMed    


  254. CHIONCEL O, Metra M
    Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock.
    Eur J Heart Fail. 2021;23:1938-1941.
    PubMed    


  255. BARAN DA
    A deceptively simple problem: the case of cardiogenic shock.
    Eur J Heart Fail. 2021;23:1952-1954.
    PubMed    


  256. WITTE KK, Kaye DM, Lipiecki J, Siminiak T, et al
    Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1971-1978.
    PubMed     Abstract available


  257. SCHRAGE B, Beer BN, Savarese G, Dabboura S, et al
    Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
    Eur J Heart Fail. 2021;23:1942-1951.
    PubMed     Abstract available


  258. LU DY, Adelsheimer A, Chan K, Yeo I, et al
    Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.
    Eur J Heart Fail. 2021;23:1927-1937.
    PubMed     Abstract available


    October 2021
  259. FRASER AG, Szymanski P
    Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility.
    Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2373.
    PubMed    


  260. WEI D, Li J, Janszky I, Chen H, et al
    Death of a child and the risk of heart failure: a population-based cohort study from Denmark and Sweden.
    Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2372.
    PubMed     Abstract available


  261. OMEROVIC E, Citro R, Bossone E, Redfors B, et al
    Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 2: vascular pathophysiology, gend
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2368.
    PubMed     Abstract available


  262. MINANA G, Bayes-Genis A, Nunez J
    Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind.
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2365.
    PubMed    


  263. MARTENS P
    Detecting Subclinical Congestion in Stage A/B pre-Heart Failure - A glimpse into the future?
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2366.
    PubMed    


  264. TROMP J, Packer M, Lam C
    The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal.
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2363.
    PubMed    


  265. ADAMO M, Metra M
    Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2362.
    PubMed    


  266. CUTHBERT JJ, Pellicori P, Flockton R, Kallvikbacka-Bennett A, et al
    The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure.
    Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2353.
    PubMed     Abstract available


  267. LAUDER L, Pereira TV, Degenhardt MC, Ewen S, et al
    Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2360.
    PubMed     Abstract available


  268. LOGEART D, Berthelot E, Bihry N, Eschalier R, et al
    Early and short-term intensive management after discharge for patients hospitalized with acute heart failure, a randomized study (ECAD-HF).
    Eur J Heart Fail. 2021 Oct 9. doi: 10.1002/ejhf.2357.
    PubMed     Abstract available


  269. KRZESINSKI P, Jankowska EA, Siebert J, Galas A, et al
    Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET Study): a randomised controlled trial.
    Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2358.
    PubMed     Abstract available


  270. ROSANO G, Jankowska EA, Ray R, Metra M, et al
    COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2356.
    PubMed     Abstract available



  271. Corrigendum to 'Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials' [Eur J Heart Fail 2016;18:684-692].
    Eur J Heart Fail. 2021 Oct 4. doi: 10.1002/ejhf.2354.
    PubMed    


  272. TOMASONI D, Adamo M, Metra M
    October 2021 at a glance: focus on imaging, biomarkers and comorbidities.
    Eur J Heart Fail. 2021;23:1569-1571.
    PubMed    


  273. PACKER M, Zannad F, Butler J, Filippatos G, et al
    Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2021;23:1798-1799.
    PubMed    


  274. BEN GAL T, Ben Avraham B, Milicic D, Crespo-Leiro MG, et al
    Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.
    Eur J Heart Fail. 2021;23:1597-1609.
    PubMed     Abstract available


  275. GUAZZI M, Adamo M
    Cardiac output in severe tricuspid regurgitation: when more is less.
    Eur J Heart Fail. 2021;23:1795-1797.
    PubMed    


  276. CAMPOCHIARO C, De Luca G, Dagna L
    Cardiac immune-related adverse events: an immune-cardio-oncology puzzle.
    Eur J Heart Fail. 2021;23:1748-1749.
    PubMed    


  277. USMAN MS, Pitt B, Butler J
    Target trial emulations: bridging the gap between clinical trial and real-world data.
    Eur J Heart Fail. 2021;23:1708-1711.
    PubMed    


  278. ENRIQUEZ-SARANO M, Benfari G, Messika-Zeitoun D, Grigioni F, et al
    Functional mitral regurgitation: a proportionate or disproportionate focus of attention?
    Eur J Heart Fail. 2021;23:1759-1762.
    PubMed    


  279. PATTERSON T, Gregson J, Erglis A, Joseph J, et al
    Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.
    Eur J Heart Fail. 2021;23:1775-1783.
    PubMed     Abstract available


  280. CAIFFA T, De Luca A, Biagini E, Lupi L, et al
    Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1765-1774.
    PubMed     Abstract available


  281. UNTERHUBER M, Kresoja KP, Besler C, Rommel KP, et al
    Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis.
    Eur J Heart Fail. 2021;23:1784-1794.
    PubMed     Abstract available


  282. RIZZO S, De Gaspari M, Basso C
    Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria.
    Eur J Heart Fail. 2021;23:1736-1738.
    PubMed    


  283. ZENG DX, Jiang JH
    Letter regarding the article 'Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'.
    Eur J Heart Fail. 2021;23:1800.
    PubMed    


  284. TREVISAN M, Fu EL, Xu Y, Savarese G, et al
    Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
    Eur J Heart Fail. 2021;23:1698-1707.
    PubMed     Abstract available


  285. RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
    Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Eur J Heart Fail. 2021;23:1739-1747.
    PubMed     Abstract available


  286. PALASKAS NL, Segura A, Lelenwa L, Siddiqui BA, et al
    Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Eur J Heart Fail. 2021;23:1725-1735.
    PubMed     Abstract available


    September 2021
  287. HALLE M, Schobel C, Winzer EB, Bernhardt P, et al
    A randomized clinical trial on the short-term effects of 12 weeks sacubitril/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY-HF study.
    Eur J Heart Fail. 2021 Sep 30. doi: 10.1002/ejhf.2355.
    PubMed     Abstract available


  288. CODINA P, Lupon J, Borrellas A, Spitaleri G, et al
    Head-to-head comparison of contemporary heart failure risk scores.
    Eur J Heart Fail. 2021 Sep 24. doi: 10.1002/ejhf.2352.
    PubMed     Abstract available


  289. YEOH SE, Dewan P, Serenelli M, Ferreira JP, et al
    Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
    Eur J Heart Fail. 2021 Sep 18. doi: 10.1002/ejhf.2350.
    PubMed     Abstract available



  290. Corrigendum to 'Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction' [Eur J Heart Fail 2021; 23, 983-991.].
    Eur J Heart Fail. 2021 Sep 12. doi: 10.1002/ejhf.2341.
    PubMed    


  291. KAMMERLANDER AA, Nitsche C, Dona C, Koschutnik M, et al
    Heart Failure with Preserved Ejection Fraction after Left-sided Valve Surgery: Prevalent and Relevant.
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2345.
    PubMed     Abstract available


  292. COMPAGNUCCI P, Dello Russo A, Casella M
    Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy. Letter regarding the article 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Fai
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2340.
    PubMed    


  293. MEIJERS WC, Bayes-Genis A, Mebazaa A, Bauersachs J, et al
    Circulating Heart Failure Biomarkers beyond Natriuretic Peptides: updated review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2346.
    PubMed     Abstract available


  294. INCIARDI RM, Solomon SD
    Cardiac Mechanics Assessment and the Risk of Heart Failure in the General Population.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2342.
    PubMed    


  295. HEUSSER K, Wittkoepper J, Bara C, Haverich A, et al
    Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end-stage heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2344.
    PubMed     Abstract available


  296. BARTKO PE, Kreidel F, von Bardeleben RS, Goliasch G, et al
    Mitral regurgitation tips the scales in acute or worsening heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2343.
    PubMed    


  297. MOURA B, Aimo A, Al-Mohammad A, Flammer A, et al
    Integration of imaging and circulating biomarkers in heart failure: a Consensus Document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2021 Sep 5. doi: 10.1002/ejhf.2339.
    PubMed     Abstract available


  298. BECHER PM, Schrage B, Benson L, Fudim M, et al
    Phenotyping Heart Failure Patients for Iron Deficiency and Use of Intravenous Iron Therapy: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
    PubMed     Abstract available



  299. Abstracts of the Heart Failure 2021 and the World Congress on Acute Heart Failure, 29 June - 1 July 2021, Online Congress.
    Eur J Heart Fail. 2021;23 Suppl 2:2-322.
    PubMed    


  300. CRESPO-LEIRO MG, Barge-Caballero E, Gustafsson F
    Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore.
    Eur J Heart Fail. 2021;23:1560-1562.
    PubMed    


  301. ITZHAKI BEN ZADOK O, Shaul AA, Ben-Avraham B, Yaari V, et al
    Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Eur J Heart Fail. 2021;23:1555-1559.
    PubMed     Abstract available


  302. TOMASONI D, Adamo M, Metra M
    September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment.
    Eur J Heart Fail. 2021;23:1419-1421.
    PubMed    


  303. BLUMER V, Gayowsky A, Xie F, Greene SJ, et al
    Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial.
    Eur J Heart Fail. 2021;23:1488-1498.
    PubMed     Abstract available


  304. TOPS LF, Coats AJS, Ben Gal T
    The ever-changing field of mechanical circulatory support: new challenges at the advent of the 'single device era'.
    Eur J Heart Fail. 2021;23:1428-1431.
    PubMed    


  305. AIMO A, Saccaro LF, Borrelli C, Fabiani I, et al
    The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease.
    Eur J Heart Fail. 2021;23:1458-1467.
    PubMed     Abstract available


  306. YUZEFPOLSKAYA M, Colombo PC
    Reply to 'Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus'.
    Eur J Heart Fail. 2021;23:1566-1567.
    PubMed    


  307. NURJADI D, Ruhparwar A, Zanger P
    Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus. Letter regarding the article 'Association of preoperative infections, nasal Staphylococcus aur
    Eur J Heart Fail. 2021;23:1566.
    PubMed    


  308. FERREIRA JP, Konstam MA, McMurray JJV, Butler J, et al
    Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
    Eur J Heart Fail. 2021;23:1477-1484.
    PubMed     Abstract available


    August 2021
  309. CARBONE S, DaSilva-deAbreu A, Lavie CJ
    The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2336.
    PubMed    


  310. DANDEL M, Hetzer R
    Benefits of Transvenous Mitral Annuloplasty in Heart Failure with Lower Degrees of Functional Mitral Regurgitation. Letter regarding the article ' Treating symptoms and reversing remodeling: clinical and echocardiographic 1-year outcomes with percutan
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2335.
    PubMed    


  311. PUGLIESE NR, Paneni F, Mazzola M, De Biase N, et al
    Impact of epicardial adipose tissue on cardiovascular hemodynamics, metabolic profile, and prognosis in heart failure.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2337.
    PubMed     Abstract available


  312. RICHARDS AM, Pemberton CJ
    Progress in proteomic probing for pathogenic pathways in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Aug 18. doi: 10.1002/ejhf.2332.
    PubMed    


  313. STEWART COATS A
    Figures of the Heart Failure Association: Professor Dr. Wilfried Mullens, Board Member, 2018-2022, Coordinator of Study Group of Cardiorenal Dysfunction and Co-coordinator of Committee on Cardiac Devices.
    Eur J Heart Fail. 2021 Aug 9. doi: 10.1002/ejhf.2325.
    PubMed    


  314. STEWART COATS AJ
    Figures of the Heart Failure Association: Loreena Hill (HFA Board Member and Nurse representative 2016-2020, and HFA Secretary 2020-2022).
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2323.
    PubMed    


  315. STEWART COATS AJ
    The HFA further develops it educational engagement working together on an MSc in Heart Failure with St George's Hospital in London.
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2324.
    PubMed    


  316. TOMASONI D, Adamo M, Metra M
    August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices.
    Eur J Heart Fail. 2021;23:1247-1249.
    PubMed    


  317. HERRINGTON WG, Savarese G, Haynes R, Marx N, et al
    Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Eur J Heart Fail. 2021;23:1260-1275.
    PubMed     Abstract available


  318. SINAGRA G, Dal Ferro M, Gigli M
    The heart of dystrophinopathies.
    Eur J Heart Fail. 2021;23:1287-1289.
    PubMed    


  319. GUSTAFSSON F, Netuka I
    Progressive elimination of adverse events: the key to success for left ventricular assist devices.
    Eur J Heart Fail. 2021;23:1401-1403.
    PubMed    


  320. ROSARIO KF, DeVore AD
    Can we prevent infections in patients with left ventricular assist devices?
    Eur J Heart Fail. 2021;23:1416-1418.
    PubMed    


  321. RESTREPO-CORDOBA MA, Wahbi K, Florian AR, Jimenez-Jaimez J, et al
    Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy.
    Eur J Heart Fail. 2021;23:1276-1286.
    PubMed     Abstract available


  322. RAPEZZI C, Pavasini R, Serenelli M
    The left atrium in cardiac amyloidosis: a valuable but still underused observation window on the overall disease process.
    Eur J Heart Fail. 2021;23:1296-1299.
    PubMed    


  323. YUZEFPOLSKAYA M, Lumish HS, Javaid A, Cagliostro B, et al
    Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes.
    Eur J Heart Fail. 2021;23:1404-1415.
    PubMed     Abstract available


  324. MEHRA MR, Cleveland JC Jr, Uriel N, Cowger JA, et al
    Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.
    Eur J Heart Fail. 2021;23:1392-1400.
    PubMed     Abstract available


  325. IUNG B, Urena M
    Transcatheter mitral valve repair for primary and secondary mitral regurgitation: new insights from a nationwide registry.
    Eur J Heart Fail. 2021;23:1377-1379.
    PubMed    


  326. MINAMISAWA M, Inciardi RM, Claggett B, Cuddy SAM, et al
    Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans.
    Eur J Heart Fail. 2021;23:1290-1295.
    PubMed     Abstract available


  327. COLOMBO A, Mangieri A
    Can we set a threshold for the learning curve of MitraClip procedures?
    Eur J Heart Fail. 2021;23:1390-1391.
    PubMed    


  328. CHATTERJEE NA, Levy WC
    Looking forward and backward for sudden death risk: competing risk is everywhere.
    Eur J Heart Fail. 2021;23:1357-1360.
    PubMed    


  329. KELLER K, Hobohm L, Schmidtmann I, Munzel T, et al
    Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in Germany.
    Eur J Heart Fail. 2021;23:1380-1389.
    PubMed     Abstract available


  330. BEDOGNI F, Popolo Rubbio A, Grasso C, Adamo M, et al
    Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation.
    Eur J Heart Fail. 2021;23:1364-1376.
    PubMed     Abstract available


  331. GILL H, Chehab O, Allen C, Patterson T, et al
    The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease.
    Eur J Heart Fail. 2021;23:1325-1333.
    PubMed     Abstract available


    July 2021
  332. SKAARUP KG, Lassen MCH, Johansen ND, Sengelov M, et al
    Layer-Specific Global Longitudinal Strain and the Risk of Heart Failure and Cardiovascular Mortality in the General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Jul 29. doi: 10.1002/ejhf.2315.
    PubMed     Abstract available


  333. PANDEY A, Butler J
    Improving Exercise Tolerance & Quality of Life in Heart Failure with Preserved Ejection Fraction Time to Think Outside the Heart.
    Eur J Heart Fail. 2021 Jul 22. doi: 10.1002/ejhf.2313.
    PubMed    


  334. KHAN MS, Butler J, Greene SJ
    Simultaneous or Rapid Sequence Initiation of Medical Therapies for Heart Failure: Seeking to Avoid the Case of "Too Little, Too Late".
    Eur J Heart Fail. 2021 Jul 19. doi: 10.1002/ejhf.2311.
    PubMed    


  335. SWEDBERG K
    The clinical practise of treating patients with chronic heart failure needs to be improved.
    Eur J Heart Fail. 2021 Jul 17. doi: 10.1002/ejhf.2309.
    PubMed    


  336. ADAMSON C, Jhund PS, Docherty KF, Belohlavek J, et al
    Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
    Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
    PubMed     Abstract available


  337. MILLER RJ, Howlett JG
    Untying the Gordian Knot of Sex and Heart Failure Therapy.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2299.
    PubMed    


  338. SAVARESE G, Merlo M, Coats AJ, Metra M, et al
    Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2306.
    PubMed    


  339. ANKER MS, Tschope C
    Reply to 'Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?'
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2305.
    PubMed    


  340. GRAHAM FJ, Pellicori P, Cleland JGF, Clark AL, et al
    REPLY to a letter regarding the article "Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure".
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2304.
    PubMed    


  341. GREENE SJ, Butler J, Metra M
    Another Reason to Embrace Quadruple Medical Therapy for Heart Failure: Medications Enabling Tolerance of the Others.
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2301.
    PubMed    


  342. NUNEZ J, de la Espriella R, Minana G, Santas E, et al
    Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
    Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
    PubMed     Abstract available


  343. KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
    Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
    PubMed     Abstract available


  344. BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
    The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
    PubMed    


  345. BISSON A, Ding WY, Bodin A, Lip GYH, et al
    Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
    PubMed    


  346. CARAVITA S, Iacovoni A, Senni M
    The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2294.
    PubMed    


  347. TOMASONI D, Adamo M, Metra M
    July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy.
    Eur J Heart Fail. 2021;23:1059-1061.
    PubMed    


  348. MEHRA MR, Crandall DL, Gustafsson F, Jorde UP, et al
    Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
    Eur J Heart Fail. 2021;23:1226-1237.
    PubMed     Abstract available


  349. TURNER JM, Cox ZL, Testani JM
    Improving renal function during diuresis: useful information or just noise?
    Eur J Heart Fail. 2021;23:1131-1133.
    PubMed    


  350. AMMIRATI E, Varrenti M, Veronese G, Fanti D, et al
    Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab.
    Eur J Heart Fail. 2021;23:1242-1245.
    PubMed    


  351. PELLICORI P, Fitchett D, Kosiborod MN, Ofstad AP, et al
    Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2021;23:1085-1093.
    PubMed     Abstract available


  352. KUSCHYK J, Falk P, Demming T, Marx O, et al
    Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system.
    Eur J Heart Fail. 2021;23:1160-1169.
    PubMed     Abstract available


  353. DENIAU B, Picod A, Azibani F, Gayat E, et al
    The CLIP-based mortality score in cardiogenic shock: suitable only for cardiogenic shock?
    Eur J Heart Fail. 2021;23:1240-1242.
    PubMed    


  354. ZYMLINSKI R, Biegus J, Ponikowski P
    Not all fluid overloads are the same: some practical considerations for better decongestion.
    Eur J Heart Fail. 2021;23:1106-1109.
    PubMed    


  355. KARAMICHALAKIS N, Ikonomidis I, Parissis J, Simitsis P, et al
    Association of ventricular-arterial interaction with the response to cardiac resynchronization therapy.
    Eur J Heart Fail. 2021;23:1238-1240.
    PubMed    


  356. FINOCCHIARO G, Sinagra G, Papadakis M, Carr-White G, et al
    The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era.
    Eur J Heart Fail. 2021;23:1062-1067.
    PubMed    


    June 2021
  357. PONIKOWSKI P, Alemayehu W, Oto A, Bahit MC, et al
    Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2285.
    PubMed     Abstract available


  358. MCEWAN P, Ponikowski P, Davis JA, Rosano G, et al
    Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2270.
    PubMed     Abstract available


  359. YAFASOVA A, Butt JH, Rorth R
    Troponin - An important prognostic biomarker in patients with heart failure and reduced ejection fraction?
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2282.
    PubMed    


  360. GREENE SJ, Fonarow GC
    Clinical Inertia and Medical Therapy for Heart Failure: The Unintended Harms of "First, Do No Harm".
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2283.
    PubMed    


  361. ABDIN A, Bohm M
    Renal function and vericiguat in heart failure patients: Light at the end of the tunnel!
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2280.
    PubMed    


  362. KHAN MS, Khan F, Fonarow GC, Sreenivasan J, et al
    Dietary Interventions and Nutritional Supplements for Heart Failure: A Systematic Appraisal and Evidence Map.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2278.
    PubMed     Abstract available


  363. ANKER SD, Khan MS, Shahid I, Filippatos G, et al
    SGLT-2 Inhibitors in Heart Failure with Preserved Ejection Fraction Reasons for Optimism.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2279.
    PubMed    


  364. SHAH SJ, Cowie MR, Wachter R, Szecsody P, et al
    Baseline Characteristics of Patients in the PARALLAX Trial: Insights into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jun 25. doi: 10.1002/ejhf.2277.
    PubMed     Abstract available


  365. PAGNESI M, Adamo M, Sama IE, Anker SD, et al
    Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2021 Jun 23. doi: 10.1002/ejhf.2276.
    PubMed     Abstract available


  366. BARATTO C, Caravita S, Parati G
    HFpEF and COVID-19: which comes first, the chicken or the egg? Letter regarding the article "Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings".
    Eur J Heart Fail. 2021 Jun 17. doi: 10.1002/ejhf.2273.
    PubMed    


  367. SAVARESE G, Bodegard J, Norhammar A, Sartipy P, et al
    Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Eur J Heart Fail. 2021 Jun 15. doi: 10.1002/ejhf.2271.
    PubMed     Abstract available


  368. RICHARDS AM, Pemberton CJ
    Urinary Peptides in Heart Failure - the need for care with pees and cues.
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2269.
    PubMed    


  369. PATEL RB, Shah SJ
    The Splanchnic Reservoir: An Oasis for Blood Volume in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2268.
    PubMed    


  370. STOLFO D, Savarese G
    Association Between Heart Failure and Cancer: Is Gender the Answer?
    Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ejhf.2261.
    PubMed    


  371. BHATT AS, Vaduganathan M, Claggett BL, Liu J, et al
    Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial.
    Eur J Heart Fail. 2021 Jun 7. doi: 10.1002/ejhf.2259.
    PubMed     Abstract available


  372. TOMASONI D, Adamo M, Metra M
    June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment.
    Eur J Heart Fail. 2021;23:847-849.
    PubMed    


  373. SEGAR MW, Pandey A
    Omics, machine learning, and personalized medicine in heart failure with preserved ejection fraction: promising future or false hope?
    Eur J Heart Fail. 2021;23:992-994.
    PubMed    


  374. FERREIRA JP
    Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis.
    Eur J Heart Fail. 2021;23:945-946.
    PubMed    


  375. RAAFS AG, Verdonschot JAJ, Henkens MTHM, Adriaans BP, et al
    The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment o
    Eur J Heart Fail. 2021;23:933-944.
    PubMed     Abstract available


  376. GARCIA-PAVIA P, Bengel F, Brito D, Damy T, et al
    Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.
    Eur J Heart Fail. 2021;23:895-905.
    PubMed     Abstract available


  377. HAVERKAMP W, Butler J, Anker SD
    Can we trust a smartwatch ECG? Potential and limitations.
    Eur J Heart Fail. 2021;23:850-853.
    PubMed    


  378. SATTAR N, Januzzi JL
    Can biomarkers help find the 'sweet spot' for treating patients with diabetes?
    Eur J Heart Fail. 2021;23:1037-1039.
    PubMed    


  379. PARCHA V, Arora P
    Sodium-glucose co-transporter 2 inhibitors: strength of evidence for a cardio-renal-metabolic therapy.
    Eur J Heart Fail. 2021;23:1009-1011.
    PubMed    


  380. GREENBERG B, Adler E, Campagnari C, Yagil A, et al
    A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:995-999.
    PubMed     Abstract available


  381. DAMY T, Sultan MB, Witteles R
    Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:1057-1058.
    PubMed    


    May 2021
  382. PACKER M, Januzzi JL Jr, Ferreira JP, Anker SD, et al
    Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2256.
    PubMed     Abstract available


  383. BUTLER J, Yang M, Sawhney B, Chakladar S, et al
    Treatment Patterns and Clinical Outcomes Among Patients <65 Years with a Worsening Heart Failure Event.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2252.
    PubMed     Abstract available


  384. SORIMACHI H, Burkhoff D, Verbrugge FH, Omote K, et al
    Obesity, Venous Capacitance, and Venous Compliance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2254.
    PubMed     Abstract available


  385. SOLOMON SD, de Boer RA, DeMets D, Hernandez AF, et al
    Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2249.
    PubMed     Abstract available


  386. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency contributes to the resistance to endogenous erythropoietin in anaemic heart failure patients.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2253.
    PubMed     Abstract available


  387. GRAHAM FJ, Masini G, Pellicori P, Cleland JGF, et al
    Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2251.
    PubMed     Abstract available


  388. FADINI GP, Avogaro A
    A simple way to spotlight hidden heart failure in type 2 diabetes?
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2258.
    PubMed    


  389. VAN SPALL HG, Averbuch T, Damman K, Voors AA, et al
    Risk and Risk Reduction In Trials of Heart Failure with Reduced Ejection Fraction: Absolute or Relative?
    Eur J Heart Fail. 2021 May 26. doi: 10.1002/ejhf.2248.
    PubMed    


  390. SEFEROVIC PM, Tsutsui H, McNamara DM, Ristic AD, et al
    Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
    Eur J Heart Fail. 2021 May 19. doi: 10.1002/ejhf.2190.
    PubMed     Abstract available


  391. VOORS AA, Mulder H, Reyes E, Cowie MR, et al
    Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
    Eur J Heart Fail. 2021 May 17. doi: 10.1002/ejhf.2221.
    PubMed     Abstract available


  392. BRAUNWALD E
    The War on Heart Failure.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2217.
    PubMed    


  393. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218.
    PubMed    


  394. BISTOLA V, Simitsis P, Parissis J, Ouwerkerk W, et al
    Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2219.
    PubMed     Abstract available


  395. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 8. doi: 10.1002/ejhf.2214.
    PubMed    


  396. TOCCHETTI CG, Mercurio V, Maack C
    The multifaceted mechanisms of nitroxyl in heart failure: Inodilator or "only" vasodilator?
    Eur J Heart Fail. 2021 May 2. doi: 10.1002/ejhf.2204.
    PubMed    


  397. HILL L, Lambrinou E, Antoniou S
    Optimizing evidence-based heart failure medication: Every contact counts.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2213.
    PubMed    


  398. ROSANO GMC, Moura B, Metra M, Bauersachs J, et al
    Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2206.
    PubMed    


  399. LEEDY DJ, Reding KW, Vasbinder AL, Anderson GL, et al
    The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2207.
    PubMed     Abstract available


  400. MALEK F, Gajewski P, Zymlinski R, Janczak D, et al
    Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2209.
    PubMed     Abstract available


  401. MULDER BA, van Veldhuisen DJ, Rienstra M
    Sudden cardiac death in heart failure: more than meets the eye.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2212.
    PubMed    


  402. HADZIBEGOVIC S, Lena A, Churchill TW, Ho JE, et al
    Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2210.
    PubMed     Abstract available


  403. TOMASONI D, Adamo M, Metra M
    May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:691-692.
    PubMed    


  404. MULLENS W, Martens P, Witte K, Cowie MR, et al
    Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
    Eur J Heart Fail. 2021;23:844-845.
    PubMed    


  405. TOMASONI D, Coats AJS
    The Altmetric Attention Score: how science tries to meet social media.
    Eur J Heart Fail. 2021;23:693-697.
    PubMed    


  406. SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
    A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
    Eur J Heart Fail. 2021;23:785-796.
    PubMed     Abstract available


  407. KHEDRAKI R, Tang WHW
    Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
    Eur J Heart Fail. 2021;23:740-742.
    PubMed    


  408. VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
    Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
    Eur J Heart Fail. 2021;23:842-843.
    PubMed    


  409. LOARDI C, Zanobini M
    Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
    Eur J Heart Fail. 2021;23:841-842.
    PubMed    


  410. BHATT AS, Yanamandala M, Konstam MA
    For vaptans, as for life, balance is better.
    Eur J Heart Fail. 2021;23:751-753.
    PubMed    


  411. SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
    The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:838-840.
    PubMed    


    April 2021
  412. FRASER AG, Tschope C, de Boer RA
    Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction - knowing more and understanding less?
    Eur J Heart Fail. 2021 Apr 30. doi: 10.1002/ejhf.2205.
    PubMed    


  413. BEUSEKAMP JC, Tromp J, Boorsma EM, Heerspink HJL, et al
    Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2021 Apr 26. doi: 10.1002/ejhf.2197.
    PubMed    


  414. FUDIM M, Ponikowski P, Burkhoff D, Dunlap M, et al
    Splanchnic Nerve Modulation in Heart Failure: Mechanistic Overview, Initial Clinical Experience, and Safety Considerations.
    Eur J Heart Fail. 2021 Apr 22. doi: 10.1002/ejhf.2196.
    PubMed     Abstract available


  415. HE T, Mischak M, Clark AL, Campbell RT, et al
    Urinary peptides in heart failure: a link to molecular pathophysiology.
    Eur J Heart Fail. 2021 Apr 21. doi: 10.1002/ejhf.2195.
    PubMed     Abstract available


  416. FINE NM, Howlett JG
    Cautious optimism for machine learning techniques for prediction of heart failure outcomes.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2192.
    PubMed    


  417. NASSIF M, Butler J
    Moving in the Right Direction but Not There Yet. The Utility, Measurement, and Analysis of Health Status in Heart Failure Trials.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2193.
    PubMed    


  418. JERING KS, Claggett B, Pfeffer MA, Granger C, et al
    Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
    Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
    PubMed     Abstract available


  419. BAYES-GENIS A, Lupon J
    Heart failure is ejection fraction in motion.
    Eur J Heart Fail. 2021 Apr 9. doi: 10.1002/ejhf.2185.
    PubMed    


  420. ABRAHAM WT
    Interatrial Shunting for the Treatment of Heart Failure: An On-Demand, Self-Regulating Left Atrial Pressure Lowering System.
    Eur J Heart Fail. 2021 Apr 8. doi: 10.1002/ejhf.2184.
    PubMed    


  421. SORENSEN TB, Minamisawa M, Liu J, Claggett B, et al
    The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2181.
    PubMed    


  422. FERREIRA JP
    Cognitive function assessment for personalized heart failure disease management programmes.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2183.
    PubMed    


  423. GIRERD N, Felker GM
    The lower is not always the better: a better understanding of loop diuretics in heart failure.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2182.
    PubMed    


  424. BOLLI R, Mitrani RD, Hare JM, Pepine CJ, et al
    A Phase II Study of Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination, in Patients with Ischemic Heart Failure: The CCTRN CONCERT-HF Trial.
    Eur J Heart Fail. 2021 Apr 3. doi: 10.1002/ejhf.2178.
    PubMed     Abstract available


  425. PAGNESI M, Adamo M, Metra M
    April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure.
    Eur J Heart Fail. 2021;23:505-506.
    PubMed    


  426. BAYES-GENIS A
    The CONCERT-HF trial: a sweet and sour symphony.
    Eur J Heart Fail. 2021;23:675-676.
    PubMed    


  427. GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
    Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
    Eur J Heart Fail. 2021;23:512-526.
    PubMed     Abstract available


  428. BOUDOULAS KD, Boudoulas H
    Time and left ventricular function: the forgotten dynamic factor.
    Eur J Heart Fail. 2021;23:552-554.
    PubMed    


  429. STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
    Change in ejection fraction and long-term mortality in adults referred for echocardiography.
    Eur J Heart Fail. 2021;23:555-563.
    PubMed     Abstract available


  430. COATS AJS, Rosano G
    Treatments delayed lead to lives lost.
    Eur J Heart Fail. 2021;23:511.
    PubMed    


  431. DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
    Effect of dapagliflozin on anaemia in DAPA-HF.
    Eur J Heart Fail. 2021;23:617-628.
    PubMed     Abstract available


  432. DOBNER S
    Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:681-682.
    PubMed    


  433. HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
    Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
    Eur J Heart Fail. 2021;23:677-679.
    PubMed    


    March 2021
  434. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Ix JH, et al
    Decongestion Discriminates Risk for One Year Mortality in Patients with Improving Renal Function in Acute Heart Failure.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2179.
    PubMed     Abstract available


  435. HUYNH QL, Whitmore K, Negishi K, DePasquale CG, et al
    Cognitive Impairment as a Determinant of Response to Management Plans After Heart Failure Admission.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2177.
    PubMed     Abstract available


  436. BARAKAT MF, Amin-Youseff G, Okonko DO
    Oral Sucrosomial Iron in Heart Failure with a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2176.
    PubMed    


  437. UIJL A, Savarese G, Vaartjes I, Dahlstrom U, et al
    Identification of Distinct Phenotypic Clusters in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2169.
    PubMed     Abstract available


  438. KALOGEROPOULOS AP, Hotelling J, Skopicki HA
    Blood Counts: Targeting Anemia in Patients with Heart Failure.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2173.
    PubMed    


  439. KHAN MS, Fonarow GC, Greene SJ
    SGLT-2 Inhibitors for Heart Failure: Clinical Trial Efficacy and Clinical Practice Effectiveness.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2170.
    PubMed    


  440. WAN SH, Pandey A
    Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2171.
    PubMed    


  441. KHAN MS, Usman MS, Butler J
    Etiology Of Heart Failure Is In The Eye Of The Beholder: Does It Even Matter?
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2166.
    PubMed    


  442. PACKER M
    What Causes Exertional Dyspnea in Patients With Atrial Fibrillation? Implications for Catheter Ablation in Patients With Heart Failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2164.
    PubMed    


  443. BHATT AS, Varshney AS, Nekoui M, Moscone A, et al
    Virtual Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction: the IMPLEMENT-HF Pilot Study.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2163.
    PubMed     Abstract available


  444. METRA M, Coats AJS
    Why we love heart failure. An introduction to the universal definition of heart failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2168.
    PubMed    


  445. GUPTA P, Voors AA, Patel P, Lane D, et al
    Non-adherence to heart failure medications predicts clinical outcomes: Assessment in a single spot urine sample by liquid chromatography - tandem mass spectrometry (results of a prospective multicentre study).
    Eur J Heart Fail. 2021 Mar 23. doi: 10.1002/ejhf.2160.
    PubMed    


  446. CHIONCEL O, Stewart Coats AJ
    National Heart Failure Societies Summit 2020.
    Eur J Heart Fail. 2021 Mar 21. doi: 10.1002/ejhf.2157.
    PubMed    


  447. BOORSMA EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, et al
    Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
    Eur J Heart Fail. 2021 Mar 20. doi: 10.1002/ejhf.2158.
    PubMed     Abstract available


  448. RAVERA A, Santema BT, Sama IE, Meyer S, et al
    Quality of life in men and women with heart failure: association with outcome, and comparison of the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2154.
    PubMed     Abstract available


  449. TROMP J, Bryant JA, Jin X, van Woerden G, et al
    Epicardial fat in heart failure with reduced versus preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
    PubMed    


  450. ZIAEIAN B, Fonarow GC
    Making heart failure count.
    Eur J Heart Fail. 2021 Mar 13. doi: 10.1002/ejhf.2148.
    PubMed    


  451. PACKER M, McMurray JJV
    Rapid Evidence-Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2149.
    PubMed     Abstract available


  452. PUVREZ A, Duchenne J, Gorcsan J 3rd, Marwick TH, et al
    Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy. Letter regarding the article 'Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position s
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2150.
    PubMed    


  453. WOLSK E, Kaye DM, Komtebedde J, Shah SJ, et al
    Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 8. doi: 10.1002/ejhf.2146.
    PubMed     Abstract available


  454. WOOLLEY RJ, Ceelen D, Ouwerkerk W, Tromp J, et al
    Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
    PubMed     Abstract available


  455. CARAVITA S, Senni M, Parati G
    Reply to: 'The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome'.
    Eur J Heart Fail. 2021;23:493-494.
    PubMed    


  456. TOMASONI D, Petrie MC, Adamo M, Metra M, et al
    Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
    Eur J Heart Fail. 2021;23:486-488.
    PubMed    


  457. MAHJOUB Y, Rodenstein DO, Jounieaux V
    The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical vent
    Eur J Heart Fail. 2021;23:493.
    PubMed    


  458. PAGNESI M, Adamo M, Metra M
    March 2021 at a glance: focus on epidemiology, prevention and COVID-19.
    Eur J Heart Fail. 2021;23:347-349.
    PubMed    


  459. CARO-CODON J, Rey JR, Buno A, Iniesta AM, et al
    Characterization of NT-proBNP in a large cohort of COVID-19 patients.
    Eur J Heart Fail. 2021;23:456-464.
    PubMed     Abstract available


  460. GARG A, Seeliger B, Derda AA, Xiao K, et al
    Circulating cardiovascular microRNAs in critically ill COVID-19 patients.
    Eur J Heart Fail. 2021;23:468-475.
    PubMed     Abstract available


  461. SAVARESE G, Benson L, Sundstrom J, Lund LH, et al
    Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
    Eur J Heart Fail. 2021;23:476-485.
    PubMed     Abstract available


  462. BRAUNWALD E, Antman EM
    The path to universality.
    Eur J Heart Fail. 2021;23:381-383.
    PubMed    


  463. OLSEN FJ, Solomon SD, Biering-Sorensen T
    Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:417-419.
    PubMed    


  464. CHESSA M, Tutarel O
    Adults with congenital heart disease - we need more Europe for a better care.
    Eur J Heart Fail. 2021;23:454-455.
    PubMed    


  465. STEWART S, Playford D, Scalia GM, Currie P, et al
    Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
    Eur J Heart Fail. 2021;23:406-416.
    PubMed     Abstract available


  466. BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
    European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
    Eur J Heart Fail. 2021;23:445-453.
    PubMed     Abstract available


  467. SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
    Cumulative events in the TOPCAT trial.
    Eur J Heart Fail. 2021;23:491-492.
    PubMed    


  468. ITO M, Matsue Y, Minamino T
    Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
    Eur J Heart Fail. 2021;23:393-395.
    PubMed    


    February 2021
  469. DAUW J, Martens P, Tersalvi G, Schouteden J, et al
    Diuretic Response and Effects of Diuretic Omission in Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy.
    Eur J Heart Fail. 2021 Feb 28. doi: 10.1002/ejhf.2145.
    PubMed     Abstract available


  470. PASCUAL-FIGAL DA
    Biochemical or clinical heart failure, not so simple.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2128.
    PubMed    


  471. SEFEROVIC PM, Vardas P, Jankowska EA, Maggioni AP, et al
    The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2143.
    PubMed     Abstract available


  472. VERBRUGGE FH, Reddy YNV, Sorimachi H, Omote K, et al
    Diagnostic Scores Predict Morbidity and Mortality in Patients Hospitalised for Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2142.
    PubMed     Abstract available


  473. TURGEON RD, Barry AR, Hawkins NM, Ellis UM, et al
    Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2021 Feb 25. doi: 10.1002/ejhf.2141.
    PubMed     Abstract available


  474. LANG NN, Ahmad FA, Cleland JG, O'Connor CM, et al
    Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial.
    Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138.
    PubMed     Abstract available


  475. TROMP J, Ponikowski P, Salsali A, Angermann CE, et al
    SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2137.
    PubMed     Abstract available


  476. BHATIA K, Jain V, Gupta K, Bansal A, et al
    Prevention of Heart Failure Events with SGLT-2 Inhibitors Across a Spectrum of Cardio-Renal-Metabolic Risk.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2135.
    PubMed     Abstract available


  477. SLIWA K, van der Meer P, Petrie MC, Frogoudaki A, et al
    Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripar
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2133.
    PubMed     Abstract available


  478. FERREIRA JP, Claggett BL, Liu J, Desai AS, et al
    Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2134.
    PubMed     Abstract available


  479. BOZKURT B, Coats A, Tsutsui H
    A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Consensus Conference.
    Eur J Heart Fail. 2021 Feb 19. doi: 10.1002/ejhf.2115.
    PubMed    


  480. CHIONCEL O, Ambrosy AP, Maggioni AP
    Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2130.
    PubMed    


  481. BECHER PM, Schrage B, Ferrannini G, Benson L, et al
    Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2131.
    PubMed     Abstract available


  482. BUTT JH, Nicolau JC, Verma S, Docherty KF, et al
    Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial.
    Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
    PubMed     Abstract available


  483. RICHARDS AM
    Cardiac Myosin-Binding Protein C as a candidate biomarker in Heart Failure: rational but not revolutionary.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2126.
    PubMed    


  484. ALHAKAK AS, Teerlink JR, Lindenfeld J, Bohm M, et al
    The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2125.
    PubMed     Abstract available


  485. MILLER WL, Sorimachi H, Grill DE, Fischer K, et al
    Contributions of Cardiac Dysfunction and Volume Status to Central Hemodynamics in Chronic Heart Failure.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2121.
    PubMed     Abstract available


  486. ROHDE LE, Vaduganathan M, Claggett BL, Polanczyk CA, et al
    Dynamic Changes in Cardiovascular and Systemic Variables Prior to Sudden Cardiac Death in Heart Failure with Reduced Ejection Fraction: a PARADIGM-HF Analysis.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2120.
    PubMed     Abstract available


  487. VOLTERRANI M, Perrone V, Degli Esposti L
    Reply letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2123.
    PubMed    


  488. PAITAZOGLOU C, Bergmann MW, Ozdemir R, Pfister R, et al
    One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119.
    PubMed     Abstract available


  489. COTTER G, Davison BA, Edwards C, Takagi K, et al
    Acute Heart Failure Treatment - A Light at The End of the Tunnel?
    Eur J Heart Fail. 2021 Feb 6. doi: 10.1002/ejhf.2116.
    PubMed    


  490. CLERICO A, Aimo A, Passino C
    The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals.
    Eur J Heart Fail. 2021 Feb 2. doi: 10.1002/ejhf.2112.
    PubMed    



  491. Corrigendum to 'Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:1315-1341].
    Eur J Heart Fail. 2021;23:345.
    PubMed    



  492. Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncolog
    Eur J Heart Fail. 2021;23:345.
    PubMed    


  493. SMITH N, Tampakakis E
    COVID-19 acute respiratory distress syndrome: intriguing haemodynamics of an intriguing syndrome.
    Eur J Heart Fail. 2021;23:208-210.
    PubMed    


  494. PAGNESI M, Adamo M, Metra M
    February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
    Eur J Heart Fail. 2021;23:201-202.
    PubMed    


  495. STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
    Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
    Eur J Heart Fail. 2021;23:205-207.
    PubMed    


  496. ARNOLD SV, Butler J, Spertus JA
    Standardizing the standard: reporting health status in clinical trials.
    Eur J Heart Fail. 2021;23:203-204.
    PubMed    


  497. CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
    Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:217-230.
    PubMed     Abstract available


  498. PERLINI S, Mussinelli R, Salinaro F
    New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:290-292.
    PubMed    


  499. LYLE MA, Cooper LT
    Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
    Eur J Heart Fail. 2021;23:310-311.
    PubMed    


  500. RAPEZZI C, Aimo A, Emdin M
    Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
    Eur J Heart Fail. 2021;23:286-289.
    PubMed    


  501. ASLEH R, Amir O, Kushwaha SS
    Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
    Eur J Heart Fail. 2021;23:335-338.
    PubMed    


  502. HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
    Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
    Eur J Heart Fail. 2021;23:302-309.
    PubMed     Abstract available


  503. BONDERMAN D
    How to ATTR-ACT the perfect match?
    Eur J Heart Fail. 2021;23:275-276.
    PubMed    


  504. RAPEZZI C, Giannini F, Campo G
    Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
    Eur J Heart Fail. 2021;23:259-263.
    PubMed    


  505. BEZARD M, Kharoubi M, Galat A, Poullot E, et al
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Eur J Heart Fail. 2021;23:264-274.
    PubMed     Abstract available


  506. DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
    Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Eur J Heart Fail. 2021;23:277-285.
    PubMed     Abstract available


  507. NICOL M, Deney A, Lairez O, Vergaro G, et al
    Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:231-239.
    PubMed     Abstract available


  508. ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
    Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:250-258.
    PubMed     Abstract available


  509. SINAGRA G, Porcari A, Gentile P, Artico J, et al
    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
    Eur J Heart Fail. 2021;23:211-216.
    PubMed     Abstract available


    January 2021
  510. CANEPA M, Ameri P, Lainscak M
    COPD and comorbidities in heart failure: the next frontier of SGLT2 inhibitors?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2109.
    PubMed    


  511. PETRIE MC, Lee MMY, Docherty KF
    Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2108.
    PubMed    


  512. DOCHERTY KF, Vaduganathan M
    OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure.
    Eur J Heart Fail. 2021 Jan 22. doi: 10.1002/ejhf.2106.
    PubMed    


  513. SUTHAHAR N, Meems LMG, Groothof D, Bakker SJL, et al
    Relationship between Body-Mass Index, Cardiovascular Biomarkers and Incident Heart Failure.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2102.
    PubMed     Abstract available


  514. KIMMOUN A, Takagi K, Gall E, Ishihara S, et al
    Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2103.
    PubMed     Abstract available


  515. KOZHUHAROV N, Wussler D, Kaier T, Strebel I, et al
    Cardiac Myosin-Binding Protein C in the Diagnosis and Risk Stratification of Acute Heart Failure.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2094.
    PubMed     Abstract available


  516. REDDY YNV, Stewart GM, Obokata M, Koepp KE, et al
    Peripheral and Pulmonary Effects of Inorganic-Nitrite during Exercise in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2093.
    PubMed     Abstract available


  517. KARAVIDAS A, Troganis E, Lazaros G, Balta D, et al
    Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2092.
    PubMed     Abstract available


  518. TOMASONI D, Adamo M, Metra M
    January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity.
    Eur J Heart Fail. 2021;23:1-2.
    PubMed    


  519. MULLENS W, Martens P
    Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
    Eur J Heart Fail. 2021;23:79-82.
    PubMed    


  520. FARMAKIS D, Filippatos G
    Arrhythmias in cancer: rhythm is gonna get you!
    Eur J Heart Fail. 2021;23:154-156.
    PubMed    


  521. ANKER MS, von Haehling S, Coats AJS, Riess H, et al
    Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
    Eur J Heart Fail. 2021;23:145-153.
    PubMed     Abstract available


  522. CHIONCEL O, Collins SP, Seferovic P
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
    Eur J Heart Fail. 2021;23:197-198.
    PubMed    


    December 2020
  523. PABEL S, Hamdani N, Sossalla S
    A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'.
    Eur J Heart Fail. 2020 Dec 29. doi: 10.1002/ejhf.2091.
    PubMed    


  524. DEWAN P, Docherty KF, Bengtsson O, de Boer RA, et al
    Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.
    PubMed     Abstract available


  525. ASLAM MI, Jani V, Lin B, Dunkerly-Eyring B, et al
    Pulmonary Artery Pulsatility Index Predicts Right Ventricular Myofilament Dysfunction in Advanced Human Heart Failure.
    Eur J Heart Fail. 2020 Dec 21. doi: 10.1002/ejhf.2084.
    PubMed    


  526. MORIYAMA H, Kohno T, Kohsaka S
    Letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2081.
    PubMed    


  527. DAVISON BA, Senger S, Sama IE, Koch GG, et al
    Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2077.
    PubMed     Abstract available


  528. SCHNEIDER B, Ong P
    Improving female enrolment in randomized clinical trials of heart failure with reduced ejection fraction to ensure evidence-based health care recommendations.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2078.
    PubMed    


  529. PIEPOLI MF, Hussain RI, Comin-Colet J, Dosantos R, et al
    OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Dec 13. doi: 10.1002/ejhf.2076.
    PubMed     Abstract available


  530. DOCHERTY KF, McMurray JJV
    SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure.
    Eur J Heart Fail. 2020 Dec 6. doi: 10.1002/ejhf.2075.
    PubMed    


  531. ZELNIKER TA, Morrow DA, Mosenzon O, Goodrich EL, et al
    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.
    Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073.
    PubMed     Abstract available



  532. Addendum to the article: 'Improving risk prediction in heart failure using machine learning' [Eur J Heart Fail 2020;22:139-147].
    Eur J Heart Fail. 2020;22:2399.
    PubMed    


  533. WANG N, Cao J, Lal S
    COVID-19: getting to the heart of the matter.
    Eur J Heart Fail. 2020;22:2216-2218.
    PubMed    


  534. TOMASONI D, Adamo M, Metra M
    December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
    Eur J Heart Fail. 2020;22:2173-2174.
    PubMed    


  535. LEBEK S, Tafelmeier M, Messmann R, Provaznik Z, et al
    Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Eur J Heart Fail. 2020;22:2248-2257.
    PubMed     Abstract available


  536. BHATT AS, Vaduganathan M
    Discovery and care innovation amidst a pandemic.
    Eur J Heart Fail. 2020;22:2202-2204.
    PubMed    


  537. FARMAKIS D
    Is cardio-oncology a rapidly growing field of precision medicine?
    Eur J Heart Fail. 2020;22:2310-2313.
    PubMed    


  538. KONSTAM MA
    Ventricular remodelling: an equal-opportunity prognosticator.
    Eur J Heart Fail. 2020;22:2269-2271.
    PubMed    


    November 2020
  539. PACKER M, Butler J, Filippatos G, Zannad F, et al
    Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.
    Eur J Heart Fail. 2020 Nov 30. doi: 10.1002/ejhf.2065.
    PubMed     Abstract available


  540. GREENBERG B, Janvanishstaporn S, Feng S
    Reply to Letter: Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2067.
    PubMed    


  541. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2064.
    PubMed     Abstract available


  542. BOORSMA EM, Beusekamp JC, Ter Maaten JM, Figarska SM, et al
    Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2066.
    PubMed     Abstract available


  543. ANKER MS, Sanz AP, Zamorano JL, Mehra MR, et al
    Advanced cancer is also a heart failure syndrome - an hypothesis.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2071.
    PubMed     Abstract available


  544. MADELAIRE C, Kristensen SL
    Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from Australia and New Zealand.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2068.
    PubMed    


  545. D'AMARIO D, Borovac JA, Crea F
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2069.
    PubMed    


  546. HALLIDAY BP, Owen R, Gregson J, Vassiliou V, et al
    Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy - insights from TRED-HF.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2063.
    PubMed     Abstract available


  547. CANEPA M, Kapelios CJ, Lund LH
    Acknowledging the complex puzzle that links heart failure hospitalizations and outcomes.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2061.
    PubMed    


  548. DONAL E, Galli E, Paven E, Sade LE, et al
    Haemodynamic evaluation: a key tool for heart failure management.
    Eur J Heart Fail. 2020 Nov 20. doi: 10.1002/ejhf.2055.
    PubMed    


  549. BIEGUS J, Zymlinski R, Testani J, Marciniak D, et al
    Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high risk acute heart failure patients.
    Eur J Heart Fail. 2020 Nov 14. doi: 10.1002/ejhf.2053.
    PubMed     Abstract available


  550. TOMASONI D, Inciardi RM, Lombardi CM, Tedino C, et al
    Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2052.
    PubMed     Abstract available


  551. VERNOOY K, Brunner-La Rocca HP
    The importance of the electrocardiographic follow-up in heart failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2054.
    PubMed    


  552. DUSI V, Vitolo V, Frigerio L, Totaro R, et al
    The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056.
    PubMed    


  553. STARWALT JL, Ho AF, Wang H
    Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 8. doi: 10.1002/ejhf.2050.
    PubMed    


  554. KRESOJA KP, Rommel KP, Thiele H, Lurz P, et al
    Response to the letter regarding the article: Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Nov 4. doi: 10.1002/ejhf.2048.
    PubMed    


  555. KONIG S, Hohenstein S, Meier-Hellmann A, Kuhlen R, et al
    In-hospital Care in Acute Heart Failure during the COVID-19 Pandemic: Insights from the German-wide Helios Hospital Network.
    Eur J Heart Fail. 2020 Nov 2. doi: 10.1002/ejhf.2044.
    PubMed     Abstract available


  556. FABRIS E, Sinagra G, Valgimigli M
    Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy.
    Eur J Heart Fail. 2020 Nov 1. doi: 10.1002/ejhf.2045.
    PubMed    


  557. VOLTERRANI M, Perrone V, Sangiorgi D, Giacomini E, et al
    Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Eur J Heart Fail. 2020;22:2049-2055.
    PubMed     Abstract available



  558. Corrigendum to 'Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort' [Eur J Heart Fail 2019;21:1231-1244].
    Eur J Heart Fail. 2020;22:2172.
    PubMed    


  559. JANKOWSKA EA, Tkaczyszyn M, Ponikowski P
    Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?
    Eur J Heart Fail. 2020;22:2047-2048.
    PubMed    


  560. RICHARDS AM
    Beating the bushes for biomarkers.
    Eur J Heart Fail. 2020;22:2075-2077.
    PubMed    


  561. OKWUOSA TM, Keramida K, Filippatos G, Yancy CW, et al
    Cancer therapy and the heart; the necessity to calibrate risk.
    Eur J Heart Fail. 2020;22:1961-1965.
    PubMed    


  562. SEFEROVIC PM, Polovina M
    In search of a 'safety zone' for glycaemic control: association between glycosylated haemoglobin levels and outcomes in patients with type 2 diabetes and cardiovascular disease.
    Eur J Heart Fail. 2020;22:2035-2037.
    PubMed    


  563. KEHLER DS, Arora RC
    Frailty and the failing heart do not travel alone.
    Eur J Heart Fail. 2020;22:2120-2122.
    PubMed    


  564. COWIE MR
    DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2020;22:2157-2159.
    PubMed    


    October 2020
  565. KOUDSTAAL S, Den Ruijter HM, Peters SAE
    Sex Differences and Heart Failure - A Story of Two Tales.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2041.
    PubMed    


  566. WAGNER J, Ambrosy AP
    Hospitalizations for Heart Failure and Mortality Risk During the Evolving Coronavirus Disease 2019 Pandemic - The Wave May Break but A Dangerous Undertow Persists.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2043.
    PubMed    


  567. AHMED F
    Letter regarding the article Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2037.
    PubMed    


  568. PELLICORI P, Platz E, Dauw J, Ter Maaten JM, et al
    Ultrasound imaging of congestion in heart failure - Examinations beyond the heart.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2032.
    PubMed     Abstract available


  569. WHITELAW S, Sullivan K, Eliya Y, Alruwayeh M, et al
    Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2034.
    PubMed     Abstract available


  570. KLOMPSTRA L, Kyriakou M, Lambrinou E, Piepoli MF, et al
    Measuring physical activity with activity monitors in patients with heart failure. From literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiol
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2035.
    PubMed     Abstract available


  571. SIERPINSKI R, Josiak K, Suchocki T, Wojtas-Polc K, et al
    High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2036.
    PubMed     Abstract available


  572. BEKFANI T, Fudim M, Cleland JGF, Jorbenadze A, et al
    A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2033.
    PubMed     Abstract available


  573. CULIC V, Velat I
    Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2031.
    PubMed    


  574. LABROSCIANO C, Horton D, Air T, Tavella R, et al
    Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned Readmissions Following Hospitalisation for Heart Failure in Australia and New Zealand.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2030.
    PubMed     Abstract available


  575. DE BOER RA, Hulot JS, Gabriele Tocchetti C, Aboumsallem JP, et al
    Common Mechanistic Pathways in Cancer and Heart Failure.
    Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029.
    PubMed     Abstract available


  576. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position
    Eur J Heart Fail. 2020 Oct 17. doi: 10.1002/ejhf.2026.
    PubMed     Abstract available


  577. KOEHLER J, Stengel A, Hofmann T, Wegscheider K, et al
    Telemonitoring in patients with chronic heart failure and moderate depressed symptoms - results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
    Eur J Heart Fail. 2020 Oct 15. doi: 10.1002/ejhf.2025.
    PubMed     Abstract available


  578. KASSNER A, Oezpeker C, Gummert J, Zittermann A, et al
    Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with terminal heart failure.
    Eur J Heart Fail. 2020 Oct 10. doi: 10.1002/ejhf.2021.
    PubMed    


  579. SAED ALHAKAK A, Sengelov M, Jorgensen PG, Bruun NE, et al
    Left Ventricular Systolic Ejection Time is an Independent Predictor of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 9. doi: 10.1002/ejhf.2022.
    PubMed     Abstract available


  580. ABRAHAM WT, Psotka MA, Fiuzat M, Filippatos G, et al
    Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
    Eur J Heart Fail. 2020 Oct 5. doi: 10.1002/ejhf.2018.
    PubMed     Abstract available


  581. PUDIL R, Mueller C, Celutkiene J, Henriksen PA, et al
    The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Oct 2. doi: 10.1002/ejhf.2017.
    PubMed     Abstract available


  582. COATS AJS
    Pulmonary artery pressure monitoring, a reality for Europe?
    Eur J Heart Fail. 2020;22:1905-1906.
    PubMed    


  583. GUSTAFSSON F, Lund LH, Metra M
    If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation.
    Eur J Heart Fail. 2020;22:1888-1890.
    PubMed    


  584. PARIKH PB, Tsigkas G, Kalogeropoulos AP
    Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
    Eur J Heart Fail. 2020;22:1875-1877.
    PubMed    


  585. ADAMO M, Metra M, Alfieri O
    Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results.
    Eur J Heart Fail. 2020;22:1849-1851.
    PubMed    


  586. GRIFFIN JM, Maurer MS
    Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?
    Eur J Heart Fail. 2020;22:1863-1865.
    PubMed    


  587. SCHNEIDER M, Mascherbauer J
    Improvement in nutritional status - a determinant of successful transcatheter tricuspid valve repair?
    Eur J Heart Fail. 2020;22:1837-1839.
    PubMed    


    September 2020
  588. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials.
    Eur J Heart Fail. 2020 Sep 27. doi: 10.1002/ejhf.2015.
    PubMed     Abstract available


  589. JAARSMA T, Celutkiene J, Lopatin Y, Vugrak L, et al
    Learning together: insights from the first Heart Failure Association Patient Forum.
    Eur J Heart Fail. 2020 Sep 23. doi: 10.1002/ejhf.2013.
    PubMed    


  590. COATS AJ
    Figures of the Heart Failure Association: Prof Lars H. Lund, Chair of the HFA Committee on Registries, Surveys and Epidemiology and HFA Board Member (from 2016).
    Eur J Heart Fail. 2020 Sep 23. doi: 10.1002/ejhf.2014.
    PubMed    


  591. FENG S, Janwanishstaporn S, Teerlink J, Metra M, et al
    Association of Left Ventricular Ejection Fraction with Worsening Renal Function in Patients with Acute Heart Failure: Insights from the RELAX-AHF-2 Study.
    Eur J Heart Fail. 2020 Sep 22. doi: 10.1002/ejhf.2012.
    PubMed     Abstract available


  592. FERREIRA JP, Lam CSP, Anker SD, Mehra MR, et al
    Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
    Eur J Heart Fail. 2020 Sep 21. doi: 10.1002/ejhf.2003.
    PubMed     Abstract available


  593. AHMAD A, Corban MT, Toya T, Verbrugge FH, et al
    Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Sep 19. doi: 10.1002/ejhf.2010.
    PubMed     Abstract available


  594. MCMURRAY JJ
    EMPEROR-Reduced: Confirming sodium-glucose cotransporter 2 (SGLT2) inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2006.
    PubMed    


  595. IBRAHIM NE, Pina IL, Camacho A, Bapat D, et al
    Sex-Based Differences in Biomarkers, Health Status, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2005.
    PubMed    


  596. MONDRITZKI T, Mai TA, Vogel J, Pook E, et al
    Cardiac output improvement by pecavaptan: A novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2001.
    PubMed     Abstract available


  597. JAARSMA T, Hill L, Bayes-Genis A, Brunner La Rocca HP, et al
    Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2008.
    PubMed     Abstract available


  598. TAYLOR CJ, Ordonez-Mena JM, Jones NR, Roalfe AK, et al
    National Trends in Heart Failure Mortality in Men and Women, United Kingdom, 2000-2017.
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1996.
    PubMed     Abstract available


  599. HILL L, Geller TP, Baruah R, Beattie JM, et al
    Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper.
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1994.
    PubMed     Abstract available


  600. GRAZETTE LP, Goldberger JJ
    Addressing the sudden cardiac death conundrum in heart failure with preserved ejection fraction: do we need a microscope or a telescope?
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1995.
    PubMed    


  601. HASENFUSS G
    Is myosin activation a new treatment for heart failure?
    Eur J Heart Fail. 2020 Sep 2. doi: 10.1002/ejhf.1983.
    PubMed    


  602. TOMASONI D, Adamo M, Metra M
    September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy.
    Eur J Heart Fail. 2020;22:1493-1494.
    PubMed    


  603. KALOGEROPOULOS AP, Simitsis P, Skopicki HA
    Secrets of spironolactone: continuing insights from TOPCAT Americas.
    Eur J Heart Fail. 2020;22:1625-1627.
    PubMed    


  604. RITCHIE R, Galougahi KK, Figtree GA
    Targeting longevity genes in the battle against diabetic heart disease - is there a gene delivery fountain of youth?
    Eur J Heart Fail. 2020;22:1582-1585.
    PubMed    


  605. BISTOLA V, Polyzogopoulou E, Parissis J
    A novel strategy for the management of lung congestion: targeting TRPV4 channel, the 'gate keeper' of pulmonary capillary permeability.
    Eur J Heart Fail. 2020;22:1646-1648.
    PubMed    


  606. ZIAEIAN B, Butler J, Fonarow GC
    With great power comes great... reliability.
    Eur J Heart Fail. 2020;22:1708-1710.
    PubMed    


    August 2020
  607. SRIVASTAVA A, Heywood JT
    Replacing Art with Numbers: Decongesting Congestive Heart Failure.
    Eur J Heart Fail. 2020 Aug 27. doi: 10.1002/ejhf.1980.
    PubMed    


  608. MCNAUGHTON CD, Collins SP, Testani JM
    Accelerated decline in renal function after hospitalization for acute heart failure: An opportunity to intervene, or a sign of the inevitable?
    Eur J Heart Fail. 2020 Aug 25. doi: 10.1002/ejhf.1992.
    PubMed    


  609. SELVARAJ S, Claggett BL, Pfeffer MA, Desai AS, et al
    Serum Uric Acid, Influence of Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF.
    Eur J Heart Fail. 2020 Aug 25. doi: 10.1002/ejhf.1984.
    PubMed     Abstract available


  610. REY JR, Caro-Codon J, Rosillo SO, Iniesta AM, et al
    Heart Failure In Covid-19 Patients: Prevalence, Incidence And Prognostic Implications.
    Eur J Heart Fail. 2020 Aug 24. doi: 10.1002/ejhf.1990.
    PubMed     Abstract available


  611. VERBRUGGE FH, Damman K
    Spironolactone: Diuretic or Disease-modifying Drug in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2020 Aug 19. doi: 10.1002/ejhf.1979.
    PubMed    


  612. CANNATA A, Bromage DI, Rind IA, Gregorio C, et al
    Temporal trends in decompensated heart failure and outcomes during COVID-19: A multisite report from heart failure referral centres in London.
    Eur J Heart Fail. 2020 Aug 18. doi: 10.1002/ejhf.1986.
    PubMed     Abstract available


  613. PIEK A, Suthahar N, Voors AA, de Boer RA, et al
    A combined bioinformatics, experimental and clinical approach to identify novel cardiac specific heart failure biomarkers: Is Dickkopf-3 (DKK3) a possible candidate?
    Eur J Heart Fail. 2020 Aug 18. doi: 10.1002/ejhf.1988.
    PubMed     Abstract available


  614. MCEWAN P, Darlington O, McMurray JJV, Jhund PS, et al
    Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Aug 4. doi: 10.1002/ejhf.1978.
    PubMed     Abstract available


  615. AIMO A, Georgiopoulos G, Senni M, Emdin M, et al
    Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues.
    Eur J Heart Fail. 2020 Aug 4. doi: 10.1002/ejhf.1977.
    PubMed    


  616. VADUGANATHAN M, McMurray JJV, Solomon SD
    Angiotensin Receptor-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: Lessons from PARAGON-HF.
    Eur J Heart Fail. 2020 Aug 2. doi: 10.1002/ejhf.1976.
    PubMed    


  617. KRESOJA KP, Lauten A, Orban M, Rommel KP, et al
    Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Aug 2. doi: 10.1002/ejhf.1975.
    PubMed     Abstract available


  618. HOWLETT JG
    The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020;22:1483-1485.
    PubMed    


  619. MONTGOMERY RA, Tang WHW
    A means to an end: the promise of tracking natriuresis with diuretic therapy.
    Eur J Heart Fail. 2020;22:1448-1450.
    PubMed    


    July 2020
  620. KRISTENSEN SL, Castagno D, Shen L, Jhund P, et al
    Prevalence and incidence of intraventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2020 Jul 28. doi: 10.1002/ejhf.1972.
    PubMed     Abstract available


  621. VADUGANATHAN M, Pareek M, Kristensen AMD, Biering-Sorensen T, et al
    Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Eur J Heart Fail. 2020 Jul 21. doi: 10.1002/ejhf.1971.
    PubMed     Abstract available


  622. VAN VELDHUISEN DJ, van Woerden G, Gorter TM, van Empel VPM, et al
    Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart Failure and Preserved Ejection Fraction: The VIP-HF study.
    Eur J Heart Fail. 2020 Jul 19. doi: 10.1002/ejhf.1970.
    PubMed     Abstract available


  623. MORTARA A, Margonato D
    Proactive management of heart failure by digital health: is monitoring of invasive pulmonary artery pressure the Holy Grail?
    Eur J Heart Fail. 2020 Jul 15. doi: 10.1002/ejhf.1966.
    PubMed    


  624. ISRAR MZ, Salzano A, Yazaki Y, Voors AA, et al
    Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Jul 14. doi: 10.1002/ejhf.1951.
    PubMed    


  625. QUARTA G, Gori M, Iorio A, D'Elia E, et al
    Cardiovascular magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities.
    Eur J Heart Fail. 2020 Jul 12. doi: 10.1002/ejhf.1961.
    PubMed     Abstract available


  626. CELUTKIENE J, Pudil R, Lopez-Fernandez T, Grapsa J, et al
    The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of
    Eur J Heart Fail. 2020 Jul 4. doi: 10.1002/ejhf.1957.
    PubMed     Abstract available


  627. RAO VN, Fudim M, Mentz RJ, Michos ED, et al
    Regional Adiposity and Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2020 Jul 3. doi: 10.1002/ejhf.1956.
    PubMed     Abstract available


  628. BASIC C, Rosengren A, Alehagen U, Dahlstrom U, et al
    Young patients with heart failure - clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1952.
    PubMed     Abstract available


  629. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1954.
    PubMed     Abstract available


  630. AMBROSY AP, Fitzpatrick JK, Fudim M
    Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1955.
    PubMed    



  631. Corrigendum to 'Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry' [Eur J Heart Fail 2020;22:92-102].
    Eur J Heart Fail. 2020;22:1287.
    PubMed    



  632. Corrigendum to 'Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry' [Eur J Heart Fail 2020;22:10
    Eur J Heart Fail. 2020;22:1287.
    PubMed    



  633. Corrigendum to 'Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:181-195].
    Eur J Heart Fail. 2020;22:1287.
    PubMed    


  634. EKSTROM K, Raisanen-Sokolowski A, Lehtonen J, Kupari M, et al
    Long-term outcome and its predictors in giant cell myocarditis. Letter regarding the article 'Long-term outcome and its predictors in giant cell myocarditis'.
    Eur J Heart Fail. 2020;22:1283-1284.
    PubMed    


  635. SEFEROVIC PM, Asanin M, Polovina M
    Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment.
    Eur J Heart Fail. 2020;22:1122-1124.
    PubMed    


  636. GORTER TM, van Veldhuisen DJ, Dickinson MG
    Right-sided cardiac disease: no longer the 'dark side of the heart'.
    Eur J Heart Fail. 2020;22:1226-1229.
    PubMed    


  637. INCIARDI RM, Rossi A
    Mitral regurgitation, edge-to-edge valve repair and the left atrium: one step beyond the left ventricle?
    Eur J Heart Fail. 2020;22:1211-1213.
    PubMed    


  638. SEFEROVIC PM, Polovina MM
    A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy.
    Eur J Heart Fail. 2020;22:1108-1110.
    PubMed    


  639. MICHEL L, Rassaf T, Totzeck M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Reply.
    Eur J Heart Fail. 2020;22:1285-1286.
    PubMed    


  640. AIMO A, Fabiani I, Emdin M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article 'Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.'
    Eur J Heart Fail. 2020;22:1284-1285.
    PubMed    


  641. TER MAATEN JM, Said F, Maass AH
    Factors predicting recovery of left ventricular dysfunction in non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2020;22:1171-1173.
    PubMed    


  642. ZWEERINK A, Allaart CP, Burri H
    Shifting diastolic filling from right to left in non-obstructive hypertrophic cardiomyopathy: exploring new indications for biventricular pacing.
    Eur J Heart Fail. 2020;22:1273-1275.
    PubMed    


    June 2020
  643. YAMANAKA S, Sakata Y, Nochioka K, Miura M, et al
    Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction.
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1945.
    PubMed     Abstract available


  644. HENKENS MTHM, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, et al
    Risk of bias in studies investigating novel diagnostic biomarkers for Heart Failure with Preserved Ejection Fraction. A systematic review.
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1944.
    PubMed     Abstract available


  645. MULDER BA, van Veldhuisen DJ, Rienstra M
    What should the C ("Congestive heart failure") represent in the CHA2 DS2 -VASc score?
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1946.
    PubMed    


  646. ANGERMANN CE, Assmus B, Anker SD, Asselbergs FW, et al
    Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF).
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1943.
    PubMed     Abstract available


  647. OUWERKERK W, Teng TK, Tromp J, Tay WT, et al
    Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Eur J Heart Fail. 2020 Jun 25. doi: 10.1002/ejhf.1869.
    PubMed     Abstract available


  648. BARTKO PE, Goliasch G
    Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle.
    Eur J Heart Fail. 2020 Jun 22. doi: 10.1002/ejhf.1941.
    PubMed    


  649. ANGELINI F, Bocchino PP, Frea S, De Ferrari GM, et al
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus.
    Eur J Heart Fail. 2020 Jun 22. doi: 10.1002/ejhf.1940.
    PubMed    


  650. DE FILIPPO O, D'Ascenzo F, De Ferrari GM
    Heart failure related hospitalisation and management during COVID-19 pandemic: are we ready to reflect? - REPLY.
    Eur J Heart Fail. 2020 Jun 21. doi: 10.1002/ejhf.1939.
    PubMed    


  651. VOORS AA, Tamby JF, Cleland JG, Koren M, et al
    Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
    Eur J Heart Fail. 2020 Jun 19. doi: 10.1002/ejhf.1933.
    PubMed     Abstract available


  652. GOETZE JP, Balling L, Deis T, Struck J, et al
    Bioactive adrenomedullin in plasma is associated to biventricular filling pressures in patients with advanced heart failure.
    Eur J Heart Fail. 2020 Jun 18. doi: 10.1002/ejhf.1937.
    PubMed    


  653. ZYMLINSKI R, Ponikowski P, Biegus J
    Looking at the heart failure through the prism of liver dysfunction.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1932.
    PubMed    


  654. AMBROSY AP, Chioncel O
    Improving Physical Activity and Exercise Capacity in Heart Failure Taking the First Step is Always the Hardest.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1934.
    PubMed    


  655. FARMAKIS D, Butler J, Filippatos G
    Sodium-glucose co-transporter-2 inhibitors: "A Tale of Two Sisters", diabetes and heart failure.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1935.
    PubMed    


  656. LYRA V, Parissis J, Kallergi M, Rizos E, et al
    (18) F-FDG PET/CT brain glucose metabolism as a marker of different types of depression comorbidity in chronic heart failure patients with impaired systolic function.
    Eur J Heart Fail. 2020 Jun 12. doi: 10.1002/ejhf.1866.
    PubMed     Abstract available


  657. NAZIR T
    Heart failure related hospitalisation and management during COVID-19 pandemic: are we ready to reflect?
    Eur J Heart Fail. 2020 Jun 10. doi: 10.1002/ejhf.1931.
    PubMed    


  658. FARMAKIS D, Mehra MR, Parissis J, Filippatos G, et al
    Heart failure in the course of a pandemic.
    Eur J Heart Fail. 2020 Jun 7. doi: 10.1002/ejhf.1929.
    PubMed    


  659. TARTIERE JM, Solal AC, Roubille F, Girerd N, et al
    Response to the letter "All rise! Orthostatic Hypotension in Heart Failure".
    Eur J Heart Fail. 2020 Jun 5. doi: 10.1002/ejhf.1927.
    PubMed    


  660. MATSUE Y, Kamiya K, Saito H, Saito K, et al
    Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: The FRAGILE-HF cohort study.
    Eur J Heart Fail. 2020 Jun 5. doi: 10.1002/ejhf.1926.
    PubMed     Abstract available


  661. GROENEWEGEN A, Rutten FH, Mosterd A, Hoes AW, et al
    Epidemiology of heart failure.
    Eur J Heart Fail. 2020 Jun 1. doi: 10.1002/ejhf.1858.
    PubMed     Abstract available


  662. BROMAGE DI, Cannata A, Rind IA, Gregorio C, et al
    The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic.
    Eur J Heart Fail. 2020 Jun 1. doi: 10.1002/ejhf.1925.
    PubMed     Abstract available



  663. Erratum to 'New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure' [Eur J Heart Fail 2020;22:378-380].
    Eur J Heart Fail. 2020;22:1056.
    PubMed    


  664. DE BROUWER R, van Veldhuisen DJ, de Boer RA
    Surviving the first COVID-19 wave and learning lessons for the second.
    Eur J Heart Fail. 2020;22:975-977.
    PubMed    


  665. XANTHOPOULOS A, Triposkiadis F, Starling RC
    Care for patients with ventricular assist devices and suspected COVID-19 infection.
    Eur J Heart Fail. 2020;22:937-940.
    PubMed    


  666. VAN LINTHOUT S, Klingel K, Tschope C
    SARS-CoV-2-related myocarditis-like syndromes Shakespeare's question: what's in a name?
    Eur J Heart Fail. 2020;22:922-925.
    PubMed    


  667. ADAMO M, Lombardi CM, Metra M
    June 2020 at a glance: focus on COVID-19, quality of life and comorbidities.
    Eur J Heart Fail. 2020;22:917-918.
    PubMed    


  668. BEAN DM, Kraljevic Z, Searle T, Bendayan R, et al
    Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
    Eur J Heart Fail. 2020;22:967-974.
    PubMed     Abstract available


  669. FARMAKIS D, Keramida K, Filippatos G
    Cardio-oncology services during the COVID-19 pandemic: practical considerations and challenges.
    Eur J Heart Fail. 2020;22:929-932.
    PubMed    


  670. BEN GAL T, Ben Avraham B, Abu-Hazira M, Frigerio M, et al
    The consequences of the COVID-19 pandemic for self-care in patients supported with a left ventricular assist device.
    Eur J Heart Fail. 2020;22:933-936.
    PubMed    


  671. KLEIN P, Anker SD, Wechsler A, Kelle S, et al
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
    Eur J Heart Fail. 2020;22:1053-1054.
    PubMed    


  672. FERREIRA JP
    Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold.
    Eur J Heart Fail. 2020;22:1006-1008.
    PubMed    


  673. BONIOS MJ, Kogerakis N, Adamopoulos SN
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Letter regarding the article 'Less invasive ventricular reconstruction for ischaemic heart failure'.
    Eur J Heart Fail. 2020;22:1053.
    PubMed    


    May 2020
  674. MULLENS W, Sharif F, Dupont M, Rothman AMK, et al
    Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study.
    Eur J Heart Fail. 2020 May 31. doi: 10.1002/ejhf.1870.
    PubMed     Abstract available


  675. KALOGEROPOULOS AP, Thankachen J, Butler J, Fang JC, et al
    Diuretic and Renal Effects of Spironolactone and Heart Failure Hospitalizations: A TOPCAT Americas Analysis.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1917.
    PubMed     Abstract available


  676. CHIONCEL O, Parissis J, Mebazaa A, Thiele H, et al
    Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock - A position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1922.
    PubMed     Abstract available


  677. COX ZL, Lai P, Lindenfeld J
    Deceases in Acute Heart Failure Hospitalizations during COVID-19.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1921.
    PubMed    


  678. PIEPOLI MF, Ponikowski PP, Volterrani M, Francis DP, et al
    Do Cheyne and Stokes have an important message for modern-day patients with heart failure? Yes they do.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1923.
    PubMed    


  679. SBOLLI M, Fiuzat M, Cani D, O'Connor CM, et al
    Depression and heart failure: the lonely comorbidity.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1865.
    PubMed     Abstract available


  680. EDELMANN F, Jaarsma T, Comin-Colet J, Schorr J, et al
    Rationale and Study Design of OUTSTEP-HF: A Randomized Controlled Study to Assess the Effect of Sacubitril/Valsartan and Enalapril on Physical Activity measured by Accelerometry in Patients with Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1919.
    PubMed     Abstract available


  681. BAJAJ NS, Vaduganathan M
    Using antimatter to uncover what matters: metformin effects on myocardial efficiency in heart failure.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1856.
    PubMed    


  682. LYON AR, Dent S, Stanway S, Earl H, et al
    Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Soci
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1920.
    PubMed     Abstract available


  683. ZHANG Y, Stewart Coats AJ, Zheng Z, Adamo M, et al
    Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1915.
    PubMed     Abstract available


  684. SALZANO A, D'Assante R, Stagnaro FM, Valente V, et al
    Heart failure management during COVID-19 outbreak in Italy. Telemedicine experience from a heart failure university tertiary referral centre.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1911.
    PubMed    


  685. VELAGALETI RS, Larson MG, Enserro D, Song RJ, et al
    Clinical Course after a First Episode of Heart Failure: Insights from the Framingham Heart Study.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1918.
    PubMed     Abstract available


  686. FUDIM M, Soloveva A
    All rise! Orthostatic Hypotension in Heart Failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1904.
    PubMed    


  687. FARMAKIS D, Thodi M, Elpidoforou M, Filippatos G, et al
    Assessing frailty in heart failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1905.
    PubMed    


  688. REDDY YNV, Borlaug BA
    New Insights into the Role of Left Atrial Function During Exercise in Heart Failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1903.
    PubMed    


  689. FERREIRA JP, Rossello X, Pocock SJ, Rossignol P, et al
    Spironolactone dose in Heart Failure with Preserved Ejection Fraction: findings from TOPCAT.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1909.
    PubMed     Abstract available


  690. SLIWA K, Bauersachs J, Coats AJ
    The European Society of Cardiology Heart Failure Association Study Group on Peripartum Cardiomyopathy - what has been achieved in 10 years.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1912.
    PubMed    


  691. SANTIAGO-VACAS E, Lupon J, Gavidia-Bovadilla G, Gual-Capllonch F, et al
    Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1862.
    PubMed     Abstract available


  692. ROSSIGNOL P, Williams B, Mayo MR, Warren S, et al
    Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1860.
    PubMed     Abstract available


  693. PACKER M, Lam CSP, Lund LH, Maurer MS, et al
    Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure and a Preserved Ejection Fraction: a Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1902.
    PubMed     Abstract available


  694. GIANNONI A, Borrelli C, Mirizzi G, Richerson GB, et al
    Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1854.
    PubMed     Abstract available


  695. CHEN S, Redfors B, Crowley A, Ben-Yehuda O, et al
    Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1841.
    PubMed     Abstract available


  696. GALINIER M, Roubille F, Berdague P, Brierre G, et al
    Telemonitoring versus standard of care in heart failure: a randomised multicentre trial.
    Eur J Heart Fail. 2020 May 21. doi: 10.1002/ejhf.1906.
    PubMed     Abstract available


  697. GUAZZI M, Moroni A
    The Dilemma of Renin Angiotensin System Blockers in Coronavirus Disease (Covid-19): Insights on the Lung Fluid Handling and Gas Exchange in Heart Failure Patients.
    Eur J Heart Fail. 2020 May 21. doi: 10.1002/ejhf.1910.
    PubMed    


  698. KAPELIOS CJ, Lund LH
    Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?: Reply.
    Eur J Heart Fail. 2020 May 20. doi: 10.1002/ejhf.1859.
    PubMed    


  699. PACKER M, Metra M
    Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction.
    Eur J Heart Fail. 2020 May 20. doi: 10.1002/ejhf.1857.
    PubMed     Abstract available


  700. D'AMARIO D, Restivo A, Canonico F, Rodolico D, et al
    Experience of Remote Cardiac Care during Covid-19 Pandemic: the V-LAP device in advanced heart failure.
    Eur J Heart Fail. 2020 May 19. doi: 10.1002/ejhf.1900.
    PubMed    


  701. TOMASONI D, Italia L, Adamo M, Inciardi RM, et al
    COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
    Eur J Heart Fail. 2020 May 15. doi: 10.1002/ejhf.1871.
    PubMed     Abstract available


  702. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 May 14. doi: 10.1002/ejhf.1853.
    PubMed     Abstract available


  703. VON HAEHLING S, Arzt M, Doehner W, Edelmann F, et al
    Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials.
    Eur J Heart Fail. 2020 May 11. doi: 10.1002/ejhf.1838.
    PubMed     Abstract available


  704. COATS AJS
    Exergaming for heart failure: an idea so good it just ought to work.
    Eur J Heart Fail. 2020 May 11. doi: 10.1002/ejhf.1842.
    PubMed    


  705. GLENISTER RT, McCullough PA
    Analysing risk in heart failure: a Kalium check.
    Eur J Heart Fail. 2020 May 10. doi: 10.1002/ejhf.1855.
    PubMed    


  706. CLELAND JG, Clark RA, Pellicori P, Inglis SC, et al
    Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic; the advantages of universal-access to home telemonitoring.
    Eur J Heart Fail. 2020 May 9. doi: 10.1002/ejhf.1864.
    PubMed    


  707. OUWERKERK W, Tromp J, Jin X, Jaufeerally F, et al
    Heart failure with preserved ejection fraction diagnostic scores in an Asian population.
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1851.
    PubMed    


  708. KHAN MS, Butler J, Greene SJ
    The real world of de novo heart failure: the next frontier for heart failure clinical trials?
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1844.
    PubMed    


  709. CHIONCEL O, Collins SP, Butler J
    Istaroxime in acute heart failure: the holy grail is at HORIZON?
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1843.
    PubMed    


  710. MESSIKA-ZEITOUN D, Verta P, Gregson J, Pocock SJ, et al
    Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis.
    Eur J Heart Fail. 2020 May 5. doi: 10.1002/ejhf.1830.
    PubMed     Abstract available


  711. ADAMO M, Lombardi CM, Metra M
    May 2020 at a glance: ischaemic heart failure and sex-related differences.
    Eur J Heart Fail. 2020;22:761-762.
    PubMed    


  712. TAVAZZI G, Pellegrini C, Maurelli M, Belliato M, et al
    Myocardial localization of coronavirus in COVID-19 cardiogenic shock.
    Eur J Heart Fail. 2020;22:911-915.
    PubMed     Abstract available


  713. HAWKINS NM, Osmanska J, Petrie MC
    Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism.
    Eur J Heart Fail. 2020;22:868-870.
    PubMed    


  714. BOLLI R, Kahlon A
    Time to end the war on cell therapy.
    Eur J Heart Fail. 2020;22:893-897.
    PubMed    


  715. FURTADO RHM, Bergmark B
    Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?
    Eur J Heart Fail. 2020;22:880-883.
    PubMed    


  716. CHATTERJEE NA, Levy WC
    Sudden cardiac death after myocardial infarction.
    Eur J Heart Fail. 2020;22:856-858.
    PubMed    


    April 2020
  717. CAUTELA J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, et al
    Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1835.
    PubMed     Abstract available


  718. DEWAN P, Jackson A, Jhund PS, Shen L, et al
    The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1832.
    PubMed     Abstract available


  719. ALMUFLEH A, Desai AS, Fay R, Ferreira JP, et al
    Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1848.
    PubMed     Abstract available


  720. AIMO A, Castiglione V, Lombardi CM
    Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1852.
    PubMed    


  721. ELHARRAM M, Ferreira JP, Sharma A
    The intersecting role of glycaemia and cardiac function in the development of heart failure among patients with type 2 diabetes mellitus after an acute coronary syndrome.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1845.
    PubMed    


  722. SUGIMOTO T, Barletta M, Bandera F, Generati G, et al
    Central role of left atrial dynamics in limiting exercise cardiac output increase and oxygen uptake in heart failure: insights by cardiopulmonary imaging.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1829.
    PubMed     Abstract available


  723. AIMO A, Barison A, Castiglione V, Emdin M, et al
    The unbearable underreporting of comorbidities in heart failure clinical trials.
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1846.
    PubMed    


  724. SIMONAVICIUS J, Brunner-La Rocca HP
    Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1839.
    PubMed    


  725. HARJOLA VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, et al
    Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1831.
    PubMed     Abstract available


  726. HENRI C, Mielniczuk L, O'Meara E
    Age and biomarkers in heart failure: challenging the current model to select patients for clinical trials.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1817.
    PubMed    


  727. JAARSMA T, Hill L, Stromberg A
    What is what? From a palliative care approach to specialized palliative care in heart failure management.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1823.
    PubMed    


  728. DAMMAN K, Ter Maaten JM, van der Meer P
    Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1825.
    PubMed    


  729. TROMBARA F, Apostolo A, Vignati C, Agostoni P, et al
    Why do left ventricular assist device recipients remain heart failure patients? Reply.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1824.
    PubMed    


  730. PARMA Z, Jasilek A, Greenlaw N, Ferrari R, et al
    Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1827.
    PubMed     Abstract available


  731. TRIPOSKIADIS F, Xanthopoulos A, Butler J
    From PARADIGM to PARAGON Further Evidence Supporting Continuous Heart Failure Spectrum.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1837.
    PubMed    


  732. KHAN MS, Samman Tahhan A, Vaduganathan M, Greene SJ, et al
    Trends in prevalence of comorbidities in heart failure clinical trials.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1818.
    PubMed     Abstract available


  733. MALIK ME, Madelaire C, D'Souza M, Blanche P, et al
    Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease.
    Eur J Heart Fail. 2020 Apr 4. doi: 10.1002/ejhf.1819.
    PubMed     Abstract available


  734. SAMA IE, Woolley RJ, Nauta JF, Romaine SPR, et al
    A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1811.
    PubMed     Abstract available


  735. ROSSIGNOL P, Lainscak M, Crespo-Leiro MG, Laroche C, et al
    Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1793.
    PubMed     Abstract available


  736. VAN DER WAL HH, Beverborg NG, Ter Maaten JM, Vinke JSJ, et al
    Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1801.
    PubMed    


  737. RUSSO D, Musumeci MB, Volpe M
    The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1766.
    PubMed    


  738. STIENEN S, Ferreira JP, Pitt B, Cleland JG, et al
    Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1812.
    PubMed    


  739. BUTLER J, Khan MS, Mori C, Filippatos GS, et al
    Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020 Apr 2. doi: 10.1002/ejhf.1810.
    PubMed     Abstract available


  740. KAPELIOS CJ, Laroche C, Crespo-Leiro MG, Anker SD, et al
    Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1796.
    PubMed     Abstract available


  741. DE DENUS S, Leclair G, Dube MP, St-Jean I, et al
    Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1802.
    PubMed     Abstract available


  742. GALLUZZO A, Bertaina M, Frea S
    Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients?
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1814.
    PubMed    


  743. METRA M, Lucioli P
    Corrigendum to 'Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015' [Eur J Heart Fail 2019;21:1329-1337].
    Eur J Heart Fail. 2020;22:759.
    PubMed    


  744. DE LUCA L, Savonitto S
    Composite trends of cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2020;22:673-675.
    PubMed    


    March 2020
  745. POZZOLI M, Gonzalez-Costello J, Bayes-Genis A, Sinagra G, et al
    Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1789.
    PubMed    


  746. LOARDI C, Zanobini M
    Why do left ventricular assist device recipients remain heart failure patients?
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1807.
    PubMed    


  747. DAVISON BA, Takagi K, Senger S, Koch G, et al
    Mega-trials in heart failure: effects of dilution in examination of new therapies.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1780.
    PubMed     Abstract available


  748. BUTT JH, Fosbol EL, Gerds TA, Andersson C, et al
    Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1800.
    PubMed     Abstract available


  749. STEWART GM, Johnson BD, Sprecher DL, Reddy YNV, et al
    Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1809.
    PubMed     Abstract available


  750. BOUABDALLAOUI N, Rouleau J
    Evolving towards a more realistic approach to the importance of left ventricular ejection fraction and sex in heart failure and its therapy.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1805.
    PubMed    


  751. SUTHAHAR N, Meems LMG, Ho JE, de Boer RA, et al
    Sex-related differences in contemporary biomarkers for heart failure: a review.
    Eur J Heart Fail. 2020 Mar 27. doi: 10.1002/ejhf.1771.
    PubMed     Abstract available


  752. SHIN SH, Claggett B, Pfeffer MA, Skali H, et al
    Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1790.
    PubMed     Abstract available


  753. BHATT AS, Ambrosy AP, Dunning A, DeVore AD, et al
    The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1795.
    PubMed     Abstract available


  754. KRAMER F, Voss S, Roessig L, Igl BW, et al
    Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1787.
    PubMed     Abstract available


  755. MORDI IR, Ouwerkerk W, Anker SD, Cleland JG, et al
    Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1799.
    PubMed     Abstract available


  756. SEFEROVIC PM, Piepoli MF, Lopatin Y, Jankowska E, et al
    Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document.
    Eur J Heart Fail. 2020 Mar 18. doi: 10.1002/ejhf.1784.
    PubMed     Abstract available


  757. SAHLOLLBEY N, Lee CKS, Shirin A, Joseph P, et al
    The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials.
    Eur J Heart Fail. 2020 Mar 16. doi: 10.1002/ejhf.1783.
    PubMed     Abstract available


  758. MADAN S, Mehra MR
    Gut dysbiosis and heart failure: navigating the universe within.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1792.
    PubMed    


  759. JAARSMA T, Klompstra L, Ben Gal T, Ben Avraham B, et al
    Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1754.
    PubMed    


  760. ROSSIGNOL P, Zannad F
    Hypo- and hyperkalaemia in heart failure. Navigating between Scylla and Charybdis.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1791.
    PubMed    


  761. HIRSCH VG, Tongers J, Bode J, Berliner D, et al
    Cardiac iron concentration in relation to systemic iron status and disease severity in non-ischaemic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Mar 10. doi: 10.1002/ejhf.1781.
    PubMed     Abstract available


  762. KHAN MS, Butler J, Greene SJ
    Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life.
    Eur J Heart Fail. 2020 Mar 10. doi: 10.1002/ejhf.1762.
    PubMed    


  763. REDDY YNV, Rikhi A, Obokata M, Shah SJ, et al
    Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.
    Eur J Heart Fail. 2020 Mar 9. doi: 10.1002/ejhf.1788.
    PubMed     Abstract available


  764. JANWANISHSTAPORN S, Feng S, Teerlink J, Metra M, et al
    Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial.
    Eur J Heart Fail. 2020 Mar 5. doi: 10.1002/ejhf.1772.
    PubMed     Abstract available


  765. PIESKE B, Tschope C, de Boer RA, Fraser AG, et al
    How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2020 Mar 5. doi: 10.1002/ejhf.1741.
    PubMed     Abstract available


  766. COATS AJS
    Figures of the Heart Failure Association (HFA): Dr. Rudolf de Boer, HFA Board Member (2014-2020), Chair of the Basic Science Section (2016-2018), coordinator of the Study Group on Heart Failure with Preserved Ejection Fraction, and member of the HFA s
    Eur J Heart Fail. 2020 Mar 4. doi: 10.1002/ejhf.1779.
    PubMed    


  767. DE BUYZERE ML, Delanghe JR
    Fibroblast growth factor 23 and the quest for the Holy Grail in heart failure: will the Crusaders be forced to surrender?
    Eur J Heart Fail. 2020 Mar 4. doi: 10.1002/ejhf.1786.
    PubMed    


  768. SEFEROVIC PM, Jankowska E, Coats AJS, Maggioni AP, et al
    The Heart Failure Association Atlas: rationale, objectives, and methods.
    Eur J Heart Fail. 2020 Mar 3. doi: 10.1002/ejhf.1768.
    PubMed     Abstract available


  769. DEWAN P, Jackson A, Lam CSP, Pfeffer MA, et al
    Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure.
    Eur J Heart Fail. 2020 Mar 2. doi: 10.1002/ejhf.1776.
    PubMed    


  770. COATS AJS
    Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?
    Eur J Heart Fail. 2020 Mar 1. doi: 10.1002/ejhf.1778.
    PubMed    


  771. ADAMO M, Lombardi CM, Metra M
    March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:389-390.
    PubMed    


  772. STEWART COATS AJ
    Validating the HFA-PEFF score - or how to define a disease?
    Eur J Heart Fail. 2020;22:428-431.
    PubMed    


  773. WESTIN O, Fosbol E, Gustafsson F
    Refining the role of carpal tunnel syndrome in cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:516-518.
    PubMed    


  774. SHEN L, Jhund P, McMurray J
    Dyslipidaemia, a factor worthy of adjustment: reply.
    Eur J Heart Fail. 2020;22:564-565.
    PubMed    


  775. SKELIN M, Lucijanic M, Lucijanic J
    Dyslipidaemia, a factor worthy of adjustment.
    Eur J Heart Fail. 2020;22:564.
    PubMed    


    February 2020
  776. STOLFO D, Savarese G
    Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence.
    Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1761.
    PubMed    


  777. KARASON K, Lund LH, Dalen M, Bjorklund E, et al
    Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) tr
    Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1773.
    PubMed     Abstract available


  778. THOMPSON DR, Clark AM
    Heart failure disease management interventions: time for a reappraisal.
    Eur J Heart Fail. 2020 Feb 24. doi: 10.1002/ejhf.1777.
    PubMed    


  779. BEHNES M, Schupp T, Mashayekhi K, Akin I, et al
    'Off-pump' left ventricular reconstruction - A causal and less invasive surgical option for patients with advanced systolic heart failure?
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1737.
    PubMed    


  780. DAMMAN K, Ter Maaten JM, Coster JE, Krikken JA, et al
    Clinical importance of urinary sodium excretion in acute heart failure.
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1753.
    PubMed     Abstract available


  781. KRISTENSEN SL, McMurray JJV
    Diagnosing heart failure with preserved ejection fraction - what's the score?
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1764.
    PubMed    


  782. ARMSTRONG PW, Pieske B, O'Connor CM
    Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply.
    Eur J Heart Fail. 2020 Feb 21. doi: 10.1002/ejhf.1765.
    PubMed    


  783. COOPER LB, Benson L, Mentz RJ, Savarese G, et al
    Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2020 Feb 20. doi: 10.1002/ejhf.1757.
    PubMed     Abstract available


  784. GROENEWEGEN A, Rutten FH
    Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Eur J Heart Fail. 2020 Feb 18. doi: 10.1002/ejhf.1759.
    PubMed    


  785. REDDY YNV, Borlaug BA
    Hypertension and heart failure: insights from exercise stress testing.
    Eur J Heart Fail. 2020 Feb 18. doi: 10.1002/ejhf.1760.
    PubMed    


  786. NJOROGE JN, Teerlink JR
    Systolic time intervals in patients with heart failure: time to teach new dogs old tricks.
    Eur J Heart Fail. 2020 Feb 13. doi: 10.1002/ejhf.1725.
    PubMed    


  787. STOHR R, Brandenburg VM, Heine GH, Maeder MT, et al
    Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial.
    Eur J Heart Fail. 2020 Feb 5. doi: 10.1002/ejhf.1749.
    PubMed     Abstract available


  788. JONES NR, Roalfe AK, Adoki I, Taylor CJ, et al
    Survival rates in elderly patients with heart failure: reply.
    Eur J Heart Fail. 2020 Feb 5. doi: 10.1002/ejhf.1751.
    PubMed    


  789. ADAMO M, Lombardi CM, Metra M
    February 2020 at a glance: acute heart failure and cardio-oncology.
    Eur J Heart Fail. 2020;22:171-172.
    PubMed    


  790. GRODIN JL, Rao A, Zaha VG
    Myocardial dysfunction in breast cancer survivors: 'you can observe a lot by just watching'.
    Eur J Heart Fail. 2020;22:347-349.
    PubMed    


  791. MAGLIOCCA A, Omland T, Latini R
    Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
    Eur J Heart Fail. 2020;22:300-302.
    PubMed    


  792. RAJU B, McCullough PA
    Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.
    Eur J Heart Fail. 2020;22:287-289.
    PubMed    


    January 2020
  793. BORIANI G, Imberti JF, Vitolo M
    Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1745.
    PubMed    


  794. CARUBELLI V, Zhang Y, Metra M, Lombardi C, et al
    Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1743.
    PubMed     Abstract available


  795. KALUZA J, Levitan EB, Michaelsson K, Wolk A, et al
    Anti-inflammatory diet and risk of heart failure: two prospective cohort studies.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1746.
    PubMed     Abstract available


  796. PUGLIESE NR, Mazzola M, Fabiani I, Gargani L, et al
    Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test.
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1739.
    PubMed     Abstract available


  797. MAURER MS, Packer M
    Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1702.
    PubMed    


  798. PELLICORI P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, et al
    Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1716.
    PubMed     Abstract available


  799. BUTLER J, Handelsman Y, Bakris G, Verma S, et al
    Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1708.
    PubMed     Abstract available


  800. JHUND PS
    The recurring problem of heart failure hospitalisations.
    Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1721.
    PubMed    


  801. REDDY YNV, Borlaug BA
    Left atrial myopathy in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1688.
    PubMed    


  802. KHAN MS, Memon MM, Murad MH, Vaduganathan M, et al
    Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1643.
    PubMed     Abstract available


  803. ROSSIGNOL P, Duarte K, Girerd N, Karoui M, et al
    Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1724.
    PubMed     Abstract available


  804. RIVAS-LASARTE M, Alvarez-Garcia J, Mirabet S, Sionis A, et al
    Is lung ultrasound monitoring really useful for impacting rehospitalization and mortality in worsening heart failure? Reply.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1719.
    PubMed    


  805. KLOOSTERMAN M, Santema BT, Roselli C, Nelson CP, et al
    Genetic risk and atrial fibrillation in patients with heart failure.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1735.
    PubMed     Abstract available


  806. AIMO A, Januzzi JL Jr, Vergaro G, Richards AM, et al
    Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1701.
    PubMed     Abstract available


  807. BAUERSACHS J, Veltmann C
    Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1733.
    PubMed    


  808. DAMMAN K, Beusekamp JC, Boorsma EM, Swart HP, et al
    Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1713.
    PubMed     Abstract available


  809. PETUTSCHNIGG J, Ferreira JP, Holzendorf V, Trippel TD, et al
    Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1723.
    PubMed    


  810. VAN LINTHOUT S, Rimoldi O, Tschope C, Camici PG, et al
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction - adding new pieces to the jigsaw puzzle.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1720.
    PubMed    


  811. ZAKERI R, Morgan JM, Phillips P, Kitt S, et al
    Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1709.
    PubMed     Abstract available


  812. TAMARGO M, Obokata M, Reddy YNV, Pislaru SV, et al
    Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1699.
    PubMed     Abstract available


  813. MULLENS W, Damman K, Testani JM, Martens P, et al
    Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1697.
    PubMed     Abstract available


  814. MCCLELLAND S, Zhou S, O'Connell E, Gallagher J, et al
    New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1661.
    PubMed    



  815. Corrigendum to 'Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU' [Eur J Heart Fail 2019;21:322-333].
    Eur J Heart Fail. 2020;22:170.
    PubMed    


  816. MEWTON N, Cucherat M
    To clip, or not to clip heart failure patients, that is the question.
    Eur J Heart Fail. 2020;22:16-19.
    PubMed    


  817. SCHLENDORF K, Stone GW, Abraham WT, Mack MJ, et al
    Who and when to clip: that is the question.
    Eur J Heart Fail. 2020;22:20-22.
    PubMed    


  818. HARRISON SL, Lane DA, Lip GYH
    Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes.
    Eur J Heart Fail. 2020;22:136-138.
    PubMed    


  819. HO G, Wettersten N, Greenberg B
    Implantable cardioverter-defibrillator therapy in patients with left ventricular assist devices: a shocking tale of survival.
    Eur J Heart Fail. 2020;22:29-31.
    PubMed    


  820. HELGESTAD OKL, Ravn HB, Josiassen J, Udesen NLJ, et al
    Mechanical respiratory support in cardiogenic shock: reply.
    Eur J Heart Fail. 2020;22:168-169.
    PubMed    


  821. MILLER PE, Gimenez MR, Thiele H
    Mechanical respiratory support in cardiogenic shock.
    Eur J Heart Fail. 2020;22:168.
    PubMed    


    December 2019
  822. TEERLINK JR, Davison BA, Cotter G, Maggioni AP, et al
    Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Eur J Heart Fail. 2019 Dec 30. doi: 10.1002/ejhf.1692.
    PubMed     Abstract available


  823. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. Tiny Jaarsma, HFA Board Member (2018-2020), Coordinator Patient Care: Management and Delivery Committee and Co-Chair HFA Task Force on Palliative Care.
    Eur J Heart Fail. 2019 Dec 30. doi: 10.1002/ejhf.1705.
    PubMed    


  824. PONIKOWSKI P, Kirwan BA, Anker SD, Dorobantu M, et al
    Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Eur J Heart Fail. 2019 Dec 28. doi: 10.1002/ejhf.1710.
    PubMed     Abstract available


  825. ANKER MS, von Haehling S, Papp Z, Anker SD, et al
    ESC Heart Failure receives its first impact factor.
    Eur J Heart Fail. 2019 Dec 27. doi: 10.1002/ejhf.1665.
    PubMed    


  826. DEVAUX Y, Nossent AY
    A role for m6A RNA methylation in heart failure development?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1714.
    PubMed    


  827. ANKER MS, Hulsmann M, Cleland JG
    What do patients with heart failure die from? A single assassin or a conspiracy?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1689.
    PubMed    


  828. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Mueller C, et al
    Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1642.
    PubMed     Abstract available


  829. GOSMANOVA EO, Lyubarova R
    Neutrophil gelatinase-associated lipocalin in acute heart failure: time to move on?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1684.
    PubMed    


  830. MYHRE PL, Vaduganathan M, Greene SJ
    Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1638.
    PubMed    


  831. MATHIASEN AB, Qayyum AA, Jorgensen E, Helqvist S, et al
    Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1700.
    PubMed     Abstract available


  832. LARSEN AH, Jessen N, Norrelund H, Tolbod LP, et al
    A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1656.
    PubMed     Abstract available


  833. PATEL PA, Ambrosy AP, Phelan M, Alenezi F, et al
    Association between systolic ejection time and outcomes in heart failure by ejection fraction.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1659.
    PubMed     Abstract available


  834. LAINSCAK M, Milinkovic I, Polovina M, Crespo-Leiro MG, et al
    Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2019 Dec 20. doi: 10.1002/ejhf.1645.
    PubMed     Abstract available


  835. BEUSEKAMP JC, Teng TK, Tay WT, Ouwerkerk W, et al
    Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry.
    Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1640.
    PubMed    


  836. TENG TK, Cooper L, Tay WT, Luo N, et al
    Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1648.
    PubMed    


  837. DOCHERTY KF, Shen L, Castagno D, Petrie MC, et al
    Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1682.
    PubMed     Abstract available


  838. BERULAVA T, Buchholz E, Elerdashvili V, Pena T, et al
    Changes in m6A RNA methylation contribute to heart failure progression by modulating translation.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1672.
    PubMed     Abstract available


  839. PACKER M
    Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1646.
    PubMed     Abstract available


  840. LIN F, Greenberg B
    Considering the gender gap in heart failure.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1706.
    PubMed    


  841. COATS AJS
    Heart Failure Association position papers - a new way to advance the field.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1704.
    PubMed    


  842. BHATT AS, Vaduganathan M, Butler J
    Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1675.
    PubMed    


  843. KHAN T
    Survival rates in elderly patients with heart failure.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1712.
    PubMed    


  844. YANG JH, Obokata M, Reddy YNV, Redfield MM, et al
    Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Dec 15. doi: 10.1002/ejhf.1671.
    PubMed     Abstract available


  845. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. Jelena Celutkiene, HFA Board Member (2016-2020) and co-coordinator of the Imaging Study Group of the HFA Diagnosis Committee.
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1703.
    PubMed    


  846. MORONI A, Viva T, Guazzi M
    Is lung ultrasound monitoring really useful for impacting rehospitalization and mortality in worsening heart failure?
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1707.
    PubMed    


  847. MOCKEL M, de Boer RA, Slagman AC, von Haehling S, et al
    Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1667.
    PubMed     Abstract available


  848. BAYES-GENIS A, Emdin M, Nunez J
    Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1690.
    PubMed    


  849. POLOVINA M, Lund LH, Dikic D, Petrovic-Dordevic I, et al
    Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation.
    Eur J Heart Fail. 2019 Dec 10. doi: 10.1002/ejhf.1666.
    PubMed     Abstract available


  850. KESHVANI N, Gupta A, Pandey A
    Towards global improvement in heart failure care.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1687.
    PubMed    


  851. BOHM M, Slawik J, Brueckmann M, Mattheus M, et al
    Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1663.
    PubMed     Abstract available


  852. PIESKE B, Patel MJ, Westerhout CM, Anstrom KJ, et al
    Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1664.
    PubMed     Abstract available


  853. SENNI M, Wachter R, Witte KK, Straburzynska-Migaj E, et al
    Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1670.
    PubMed     Abstract available


  854. LI L, Liu R, Jiang C, Du X, et al
    Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1630.
    PubMed     Abstract available


  855. SEFEROVIC PM, Coats AJS, Ponikowski P, Filippatos G, et al
    European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1673.
    PubMed     Abstract available


  856. CELUTKIENE J, Lainscak M, Anderson L, Gayat E, et al
    Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1678.
    PubMed     Abstract available


  857. KUAN WS, Ibrahim I, Chan SP, Li Z, et al
    Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.
    Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1660.
    PubMed     Abstract available


  858. BOMER N, Grote Beverborg N, Hoes MF, Streng KW, et al
    Selenium and outcome in heart failure.
    Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1644.
    PubMed     Abstract available


  859. JANUZZI JL JR, Ibrahim NE
    It is time for consistency in the use of biomarkers in heart failure clinical trials.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1696.
    PubMed    


  860. PANDHI P, Ter Maaten JM, Emmens JE, Struck J, et al
    Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1693.
    PubMed     Abstract available


  861. HOES MF, Tromp J, Ouwerkerk W, Bomer N, et al
    The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1674.
    PubMed     Abstract available


  862. KLEIN P, Anker SD, Wechsler A, Skalsky I, et al
    Less invasive ventricular reconstruction for ischaemic heart failure.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1669.
    PubMed     Abstract available


  863. BHATT AS, Vaduganathan M, Patel RB, Fonarow GC, et al
    Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1651.
    PubMed    


  864. GARGANI L, Ferre RM, Pang PS
    B-lines in heart failure: will comets guide us?
    Eur J Heart Fail. 2019;21:1616-1618.
    PubMed    


    November 2019
  865. O'MEARA E, Allen BG
    Cardiac remodelling patterns and proteomics: the keys to move beyond ejection fraction in heart failure?
    Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1691.
    PubMed    


  866. ROVAI S, Corra U, Piepoli M, Vignati C, et al
    Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction.
    Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1595.
    PubMed     Abstract available


  867. INCIARDI RM, Giugliano RP, Claggett B, Gupta DK, et al
    Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.
    Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1606.
    PubMed     Abstract available


  868. LOPEZ-FERNANDEZ T, Lopez-Sendon JL
    Heart failure after treatment for breast cancer: old cancer therapies, new clinical data. What do we need to complete the puzzle?
    Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1662.
    PubMed    


  869. MCALISTER FA, Ezekowitz JA, Armstrong PW
    Heart failure treatment and the art of medical decision making.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1655.
    PubMed    


  870. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Mueller C, et al
    B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1627.
    PubMed     Abstract available


  871. VAN WOERDEN G, van Veldhuisen DJ, Rienstra M, Westenbrink BD, et al
    Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1653.
    PubMed    


  872. PRIMESSNIG U, Bracic T, Levijoki J, Otsomaa L, et al
    Long-term effects of Na(+) /Ca(2+) exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Nov 24. doi: 10.1002/ejhf.1619.
    PubMed     Abstract available


  873. KAO D, Purohit S, Jhund P
    Therapeutic futility and phenotypic heterogeneity in heart failure with preserved ejection fraction: what is the role of bionic learning?
    Eur J Heart Fail. 2019 Nov 20. doi: 10.1002/ejhf.1658.
    PubMed    


  874. KHAN MS, Irfan S, Khan SU, Mehra MR, et al
    Transforming the interpretation of significance in heart failure trials.
    Eur J Heart Fail. 2019 Nov 14. doi: 10.1002/ejhf.1668.
    PubMed    


  875. BOEKEL NB, Duane FK, Jacobse JN, Hauptmann M, et al
    Heart failure after treatment for breast cancer.
    Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1620.
    PubMed     Abstract available


  876. ADLER ED, Voors AA, Klein L, Macheret F, et al
    Improving risk prediction in heart failure using machine learning.
    Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1628.
    PubMed     Abstract available


  877. NAUTA JF, Hummel YM, Tromp J, Ouwerkerk W, et al
    Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
    Eur J Heart Fail. 2019 Nov 11. doi: 10.1002/ejhf.1632.
    PubMed     Abstract available


  878. PLATZ E, Solomon SD, McMurray JJV
    Lung ultrasound: monitoring congestion in patients with heart failure.
    Eur J Heart Fail. 2019 Nov 8. doi: 10.1002/ejhf.1636.
    PubMed    


  879. CAO TH, Jones DJL, Voors AA, Quinn PA, et al
    Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
    Eur J Heart Fail. 2019 Nov 6. doi: 10.1002/ejhf.1608.
    PubMed     Abstract available


  880. ADAMO M, Lombardi CM, Metra M
    November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment.
    Eur J Heart Fail. 2019;21:1297-1298.
    PubMed    


  881. HAO G, Wang X, Chen Z, Zhang L, et al
    Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015.
    Eur J Heart Fail. 2019;21:1329-1337.
    PubMed     Abstract available


  882. GROENEWEGEN A, Rutten FH
    Decelerating trends in heart failure survival.
    Eur J Heart Fail. 2019;21:1326-1328.
    PubMed    


  883. TROMP J, Collins SP
    Dapagliflozin in heart failure: new frontiers.
    Eur J Heart Fail. 2019;21:1412-1414.
    PubMed    


    October 2019
  884. RIVAS-LASARTE M, Alvarez-Garcia J, Fernandez-Martinez J, Maestro A, et al
    Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study).
    Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1604.
    PubMed     Abstract available


  885. RAMALHO SHR, Claggett BL, Sweitzer NK, Fang JC, et al
    Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
    Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1593.
    PubMed    


  886. SULO G, Igland J, Overland S, Egeland GM, et al
    Heart failure in Norway, 2000-2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1609.
    PubMed     Abstract available


  887. VITALE C, Jankowska E, Hill L, Piepoli M, et al
    Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1611.
    PubMed     Abstract available


  888. RACHWAN RJ, Butler J, Collins SP, Cotter G, et al
    Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1607.
    PubMed     Abstract available


  889. GO YY, Allen JC Jr, Lam CSP
    Reply: in response to 'Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions' by Go et al.
    Eur J Heart Fail. 2019 Oct 21. doi: 10.1002/ejhf.1622.
    PubMed    


  890. SEGAR MW, Patel KV, Ayers C, Basit M, et al
    Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.
    Eur J Heart Fail. 2019 Oct 21. doi: 10.1002/ejhf.1621.
    PubMed     Abstract available


    September 2019
  891. WU CK, Lee JK, Hsu JC, Su MM, et al
    Myocardial adipose deposition and the development of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Sep 11. doi: 10.1002/ejhf.1617.
    PubMed     Abstract available


    July 2019
  892. PACKER M, Butler J, Filippatos GS, Jamal W, et al
    Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Eur J Heart Fail. 2019 Jul 16. doi: 10.1002/ejhf.1536.
    PubMed     Abstract available


    March 2019
  893. METRA M
    March 2019 at a glance: epidemiology and clinical trials.
    Eur J Heart Fail. 2019;21:259-260.
    PubMed    


  894. FERREIRA JP, Abreu P, McMurray JJV, van Veldhuisen DJ, et al
    Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.
    Eur J Heart Fail. 2019;21:345-351.
    PubMed     Abstract available


  895. VARDENY O, Claggett B, Kachadourian J, Desai AS, et al
    Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
    Eur J Heart Fail. 2019;21:337-341.
    PubMed     Abstract available


  896. AMBROSY AP, Stevens SR, Al-Khalidi HR, Rouleau JL, et al
    Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.
    Eur J Heart Fail. 2019;21:373-381.
    PubMed     Abstract available


  897. BUCKLEY LF, Canada JM, Carbone S, Trankle CR, et al
    Potential role for interleukin-1 in the cardio-renal syndrome.
    Eur J Heart Fail. 2019;21:385-386.
    PubMed    


  898. KUTYIFA V, Vermilye K, Solomon SD, McNitt S, et al
    Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.
    Eur J Heart Fail. 2019;21:360-369.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: